Mozambique Drug and Therapeutics Committee Workshop and Field Activities: Technical Report

August 2014
Mozambique Drug and Therapeutics Committee Workshop and Field Activities: Technical Report

Terry Green
Raouf Qawwas
Neusa Bay
Alda Mariano

August 2014
This report is made possible by the generous support of the American people through the US Agency for International Development (USAID), under the terms of cooperative agreement number AID-OAA-A-11-00021. The contents are the responsibility of Management Sciences for Health and do not necessarily reflect the views of USAID or the United States Government.

About SIAPS

The goal of the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program is to assure the availability of quality pharmaceutical products and effective pharmaceutical services to achieve desired health outcomes. Toward this end, the SIAPS result areas include improving governance, building capacity for pharmaceutical management and services, addressing information needed for decision-making in the pharmaceutical sector, strengthening financing strategies and mechanisms to improve access to medicines, and increasing quality pharmaceutical services.

Recommended Citation

This report may be reproduced if credit is given to SIAPS. Please use the following citation.


Key Words

Drug and Therapeutics Committee, rational medicine use, antimicrobial resistance, standard treatment guidelines, and medicine use evaluation
## CONTENTS

Acronyms ....................................................................................................................... iv  
Introduction ..................................................................................................................... 1  
Background ..................................................................................................................... 2  
  Drug and Therapeutics Committee Workshop ............................................................. 3  
  Recommendations and Next Steps ............................................................................ 4  
  Workshop Evaluation ................................................................................................. 4  
Field Activities .............................................................................................................. 5  
Annex A. Agenda and Objectives ................................................................................ 7  
Annex B. Lista dos participantes que assinaram a lista de presença ......................... 9  
Annex C. Participant Presentations ............................................................................ 12  
  General Recommendations ........................................................................................ 16  
Annex D. Recommendations and Next Steps .............................................................. 19  
Annex E. Standard Treatment Guideline Medicine Use Evaluation Protocol ............ 20  
Annex F. DTC Workshop Evaluation ......................................................................... 34  
Annex G. Intervention Report for Pilot Hospitals, ....................................................... 38  
Annex H: Maputo Central Hospital ........................................................................... 41  
Annex I. PowerPoint Slides for Workshop .................................................................. 44
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFH</td>
<td>Departamento de Farmacia Hospitalar (Department of Hospital Pharmacy)</td>
</tr>
<tr>
<td>DNAM</td>
<td>Direcção Nacional de Assistência Médica (National Directorate of Medical Assistance)</td>
</tr>
<tr>
<td>DTC</td>
<td>Drug and Therapeutics Committee</td>
</tr>
<tr>
<td>MISAU</td>
<td>Ministério da Saúde (Ministry of Health - Mozambique)</td>
</tr>
<tr>
<td>MUE</td>
<td>medicine use evaluation</td>
</tr>
<tr>
<td>OPD</td>
<td>outpatient department</td>
</tr>
<tr>
<td>SIAPS</td>
<td>Systems for Improved Access to Pharmaceuticals and Services [Program]</td>
</tr>
<tr>
<td>STG</td>
<td>standard treatment guideline</td>
</tr>
<tr>
<td>TOR</td>
<td>terms of reference</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
INTRODUCTION

The irrational use of medicines is a pervasive problem that threatens healthcare systems and quality of patient care in countries worldwide. The World Health Organization (WHO) estimates that 50% of patients receive unnecessary medicines and half of patients take their medicines incorrectly.

Irrational use behaviors include polypharmacy (the use of too many medicines per patient); the use of incorrect medicine(s) for a particular indication; the use of medicines with uncertain or unproven efficacy; inappropriate self-medication, particularly with prescription-only medicines; and taking medicines in incorrect dosages or for an improper duration. The inappropriate use of medicines has a number of consequences for public health, including:

- Increased mortality and morbidity
- Higher numbers of adverse medicine events
- Rising rates of antimicrobial resistance
- Rising health care costs

To counter the problems of irrational use, Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program and Ministério da Saúde (MISAU) (Ministry of Health) are working together in Mozambique to improve medicine management and use. SIAPS is seeking to create sustainable Drug and Therapeutics Committees (DTCs) to monitor and identify medicine use problems and to implement interventions to improve medicine use at the local health-facility level. SIAPS will also support the revision of the National Essential Medicines List (NEML) and development of new standard treatment guidelines (STGs) to complement those that are currently available.

This technical report provides information on the DTC workshop conducted on August 4-5, 2014, and on field visits to two hospitals in the Maputo area: Maputo Central Hospital and Matola Provincial Hospital. These field visits were designed to meet with hospital officials and DTCs, as well as to develop specific DTC activities to address medicine use problems.
BACKGROUND

SIAPS works with partners in the pharmaceutical sector and priority health programs to improve pharmaceutical services so that pharmaceutical products are not only available at service delivery points, but are also prescribed and dispensed appropriately, used correctly by patients, and monitored for safety and efficacy with the aim of achieving desired health outcomes. SIAPS provides technical support for the implementation of the national pharmacovigilance system to improve medicine safety; the creation of DTCs at hospitals to improve medicine use; the collection and analysis of medicine use information for decision-making; and the implementation of integrated supportive supervision and other supportive materials (e.g., guidelines, SOPs, training materials, and job aids) to improve the quality of pharmaceutical management and services according to established standards. Opportunities to improve patient adherence will also be identified and implemented in collaboration with partners. These interventions will be integrated and coordinated as appropriate to reinforce each other and improve the overall efficiency, cost-effectiveness, and quality of pharmaceutical services. It is expected that measurable improvements in pharmaceutical services will lead to measurable improvements in health outcomes.

A DTC orientation/training session was conducted in August 2013. This aimed to help establish DTCs, identify problems with—and solutions to improve—medicine use, and save funds and resources. Several DTCs were established after this orientation, and existing DTCs were able to strengthen their programs. A structure for DTCs, including multidisciplinary membership, terms of reference (TOR), action plans, and regular meetings, has also been established. They have also carried out basic prescribing indicator studies of medicine use and facilitated the monitoring of medicine availability and antibiotic use.

The Department of Hospital Pharmacy (DFH) at Direcção Nacional de Assistência Médica (DNAM) (National Directorate of Medical Assistance) has identified the establishment of DTCs at hospitals as a priority intervention to improve the rational use of medicines at the hospital level. SIAPS collaborated with DFH to review and define the TOR and membership profile for the committees, as well as to identify hospitals that have already established DTCs.

Between August 2013 and July 2014, two pilot hospitals in Maputo City were established and supported. Additionally, four DTCs in Maputo Province were established, and personnel were trained. SIAPS worked with related stakeholders at two central hospital DTCs within both Maputo City and Maputo Province to identify challenges related to STGs or other rational medicine use issues and consider specific interventions to address these problems. MISAU and SIAPS will help to establish two additional pilot DTCs in hospitals in the Maputo area.

All DTCs were invited to attend a national DTC workshop, sponsored by SIAPS, to share their experiences, and to determine which interventions should be implemented to encourage rational medicine use.
Drug and Therapeutics Committee Workshop

A two-day DTC workshop was developed and held to provide an overview of the role, main functions, and responsibilities of DTCs, as well as to hear from DTC participants about their experiences and accomplishments. The 49 attendees included physicians, pharmacists, and other health professionals from hospital DTCs and MISAU (annexes A and B).

Between July 23 and July 27, preparations for the DTC workshop took place. These included setting objectives and an agenda for the workshop, and developing PowerPoint presentation slides and relevant handouts. Standardized DTC training materials were used for the workshop with modifications making them specific to Mozambique.

Key topics for the workshop include:

- Participant presentations on their hospital DTCs, covering current activities, identified problems with – and barriers to – rational medicine use, future challenges, and DTC impact
- Medicine use overview
- Developing and implementing DTCs
- Interventions to improve medicine use and STGs
- Updating the revision process and encouraging better use of the National Essential Medicines List (NEML)
- Medicine Use Evaluation (MUE) – Improving medicine use through a MUE process, Recommendations and next steps

Day 1

At the opening session, the Minister of Health, Alexandre Manguele, welcomed all attendees and expressed his intention to improve the operations of DTCs and encourage rational medicine use in Mozambique. He explained that the workshop would evaluate the functions of the DTCs established in the provinces, representing a major step towards improving the use of medicines in health facilities. MISAU has been making efforts to improve pharmaceutical services in general, particularly at the hospital level. MISAU hopes to increase the number of staff members and available financial resources, expand availability of medicines and medical information, improve the management of the entire supply chain, and encourage rational medicines use and appropriate prescribing practices within the country’s hospitals.

The 11 hospital DTCs represented at the workshop each gave a presentation. Though many DTCs have only been recently formed, they have been able to identify the challenges facing rational medicine use and the changes they would like to implement. Key activities included the
monitoring of prescriptions for appropriate format (patient name, signatures, legible writing, dosing), basic medicine use studies (including evaluation of health facility prescribing indicators), and monitoring of the NEML.

The first day of the workshop concluded with an overview of international medicine use problems. DTCs worked in groups to identify the specific medicine use problems they face and identify possible solutions (annex C).

**Day 2**

On Day 2, participants took part in a number of workshops. These included sessions on:

- Developing and implementing DTCs, in which participants reviewed DTC structure and functions, with a special emphasis on establishing new DTCs.

- Interventions to improve medicine use and establish STGs, where participants discussed the importance of STGs in improving medicine use and considered case studies of successful STG implementation.

- NEML, in which participants reviewed the importance of having an NEML and the process of developing and monitoring the use of the list.

An additional session on conducting an MUE had been arranged, but MISAU representatives requested to skip this session due to time constraints, saying they wanted to spend more time discussing recommendations and next steps.

**Recommendations and Next Steps**

The SIAPS team prepared the recommendations for next steps and presented them to the Head of DFM, Tania Sitoie, for review. After approving the recommendations, she presented them to the participants. A key recommendation involves a study of the STGs in place at health facilities, including those for HIV/AIDS, malaria, and hypertension. This study will determine the existence of—and assess compliance with—STGs at health facilities, and will determine factors that contribute to their use or disuse of STGs. A detailed protocol for conducting the study will be developed by SIAPS and presented to MISAU for review and approval (annexes D and E).

**Workshop Evaluation**

Participants evaluated the workshop just before closing remarks. Evaluations showed a high level of approval of the presentations and outcomes (annex F).
FIELD ACTIVITIES

SIAPS worked with related stakeholders at two pilot hospital DTCs within both Maputo City and Maputo Province to identify specific challenges related to STGs and other rational medicine use issues, as well as to propose specific interventions for addressing these challenges.

**Thursday, August 7, 9:00 a.m.: José Macamo General Hospital**

Alda Mariano, Neusa Bay, and Terry Green traveled to the hospital, but the appointment was cancelled by the hospital’s Pharmacy Department due to an issue with visit approval.

**Friday, August 8, 9:00 a.m.: Matola Provincial Hospital**

The appointment was cancelled, again due to a lack of approval.

**Tuesday, August 12, 1:00 p.m.: Maputo Central Hospital**

Appointment was changed to Wednesday at 1:00 pm as the clinical director was not available at the original date and time.

**Wednesday, August 13, 8:00-9:30 a.m.: Matola Provincial Hospital**

Present at the meeting were Dr. Lisa Malombe, general-director of the hospital; Dr. José Sousa, clinical director; Dra. Durate Ibraimo, M.D.; and Randes Natussa, head of pharmaceutical services. This was an enthusiastic group of health professionals who expressed strong interest in receiving more support to develop a DTC and improve medicine availability and use.

José Sousa explained that medicine use problems are mainly related to the fact that this is a new hospital. A DTC has yet to be created at this hospital and would be very helpful in managing some of the medicine use problems that remain.

While there was very limited time to work with this hospital, we did develop recommendations for capacity-building activities and rational medicine use studies and interventions (annex G).

**Wednesday, August 13, 2:30-3:30 p.m.: Maputo Central Hospital**

This meeting was attended by Dr. Domingos Dias Diogo, the clinical director of the hospital and chair of the DTC, and Dr. Artur Luis, deputy chair of the DTC.

This hospital has an active DTC that is involved with many aspects of medicine use. For the clinical director, the main problems are compliance with STGs. They have only the HIV/AIDS and hypertension STGs available because he was working within the National committee responsible to develop these STGs. For the STGs discussed, hospital staff is trained, but they don’t have enough copies of the STGs. They have an internal STG on the use of antibiotics, particularly the use of 3rd generation cephalosporins, elaborated by the Antibiotics Committee.
Dr. Diogo specifically requested that a comprehensive study of antibiotic use be conducted to better understand the current situation in this 1,500 bed hospital. He wants to ensure rational use of antibiotics throughout the hospital.

Limited time was available to work with Maputo Central hospital. From this brief meeting, recommendations for the DTC were provided – see Annex H.
ANNEX A. AGENDA AND OBJECTIVES

II National Workshop of Hospital Medicine Therapeutic Committees (CHTFs)

Hospital Medicine Therapeutic Committees ensuring the Rational Use of Medicines in Mozambique

4 and 5 of August 2014 | Maputo, Mozambique

Objectives

1. Describe the process of implementation of CHTFs in Mozambique

2. Introduce the experience of CHTFs in the identification of the main problems of the use of medicines and their solutions.

3. Discuss the involvement of CHTFs in monthly requisition of medicines and prescribing habits

4. Describe the methods for monitoring and improving the use of medicines in hospitals.

5. Discuss the next steps for the CHTFs of Mozambique – projections for the future
### Day 1 | August 4, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity/Theme</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:00</td>
<td>Arrival and registration of participants</td>
<td>Protocol</td>
</tr>
<tr>
<td>08:00-08:30</td>
<td><strong>Opening ceremony</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Anthem</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intervention of the Head of the Department of Hospital Pharmacy</td>
<td>Dr. Tania Sitoie</td>
</tr>
<tr>
<td></td>
<td>Opening of the seminar</td>
<td>HE The Minister of Health-Dr. Alexandre Manguele</td>
</tr>
<tr>
<td>08:30-08:45</td>
<td>Presentation of participants</td>
<td>Protocol</td>
</tr>
<tr>
<td>08:45-09:45</td>
<td>Presentation of the activities of the Hospital Medicine Therapeutic Committees - CHTFs (Provinces of Niassa, Cabo Delgado, Nampula, Zambézia)</td>
<td>Hospital Pharmacy and Therapeutics committees (CHTFs)</td>
</tr>
<tr>
<td>09:45-10:00</td>
<td><strong>Coffee Break</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>Presentation of the activities of the Hospital Medicine Therapeutic Committees - CHTFs (Tete, Manica, Sofala, Inhambane, Gaza, Maputo City)</td>
<td>CHTFs</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td><strong>Lunch</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>13:00-13:45</td>
<td>Evaluation of the habits of prescriptions-results of studies conducted in six hospitals</td>
<td>Hélio Gemo (DFH)</td>
</tr>
<tr>
<td>13:45-16:00</td>
<td>Improving use of medicines – what needs to be improved and how?</td>
<td>Terry Green Alda Mariano</td>
</tr>
<tr>
<td></td>
<td>□ <strong>Overview of the use of medicines</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ <strong>Group project</strong></td>
<td>CHTFs</td>
</tr>
<tr>
<td>16:00-16:15</td>
<td><strong>Coffee Break</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>16:15-17:00</td>
<td>Improving use of medicines – what needs to be improved and how?</td>
<td>CHTFs</td>
</tr>
<tr>
<td></td>
<td>□ <strong>Presentation the group project</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Day 2 | August 5, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity/Theme</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Development and implementation of Hospital Medicine Therapeutic Committees (CHTFs) - key steps to make them effective</td>
<td>Terry Green Alda Mariano</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Key activities of CHTFs: finding solutions for the medicine use problems through the use of therapeutic protocols (STGs)</td>
<td>Alda Mariano Terry Green</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td><strong>Coffee Break</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>Key activities of the CHTFs, finding solutions for the medicine use problems through the list of essential medicines (EML)</td>
<td>Alda Mariano Terry Green Merana Mussá</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td><strong>Lunch</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Evaluation of the use of medicines</td>
<td>Alda Mariano Terry Green</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Recommendations and next steps to be followed by CHTFs</td>
<td>Dr. Tania Sitoie Terry Green Alda Mariano</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td><strong>Coffee Break</strong></td>
<td>Protocol</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Closing of the Seminar</td>
<td>Dr. Ussene Isse, National Directorate of Medical Assistance</td>
</tr>
</tbody>
</table>
ANNEX B. LISTA DOS PARTICIPANTES QUE ASSINARAM A LISTA DE PRESENÇA

REPÚBLICA DE MOÇAMBIQUE
MINISTÉRIO DA SAÚDE
DIRECÇÃO NACIONAL DE ASSISTÊNCIA MÉDICA
Departamento de Farmácia Hospitalar

Il Seminário Nacional dos Comités Hospitalares de Terapêutica e Farmácia (CHTFs)
Comités Hospitalares de Terapêutica e Farmácia assegurando o Uso Racional de Medicamentos em Moçambique
4 e 5 de Agosto de 2014, Maputo, Moçambique

<table>
<thead>
<tr>
<th>No.</th>
<th>Nome do participante</th>
<th>Província_Instituição</th>
<th>Categoria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abdel Raouf Quawwas</td>
<td>SIAPS/MSH_Maputo</td>
<td>Director do Projecto no País</td>
</tr>
<tr>
<td>2</td>
<td>Aisha Issufo</td>
<td>Direcção Nacional de Assistência Médica_Maputo</td>
<td>Técnica superion N1 Acção Hospitalar</td>
</tr>
<tr>
<td>3</td>
<td>Albertina Bizuekue</td>
<td>Hospital Provincial de Xai-Xai _Gaza</td>
<td>Técnica de Farmácia</td>
</tr>
<tr>
<td>4</td>
<td>Alda Mariano</td>
<td>SIAPS/MSH_Maputo</td>
<td>Consultora</td>
</tr>
<tr>
<td>5</td>
<td>Alfa António Jamisse</td>
<td>Hospital Provincial de Inhambane_Inhambane</td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>6</td>
<td>Ambari Anastácio Ambari</td>
<td>Hospital Provincial de Manica_Manica</td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>7</td>
<td>Aminofro Langa</td>
<td>Departamento de Farmácia Hospitalar/DNAM/MISAU_Maputo</td>
<td>Técnico de Farmácia</td>
</tr>
<tr>
<td>8</td>
<td>Ana Cala</td>
<td>Direcção Nacional de Assistência Médica_Maputo</td>
<td>Médica</td>
</tr>
<tr>
<td>9</td>
<td>Ana Cristina Fernandes</td>
<td>Organização Mundial da Saúde_Maputo</td>
<td>National Program Officer – Essential Drug &amp; Medicine</td>
</tr>
<tr>
<td></td>
<td>Nome</td>
<td>Hospital/Departamento</td>
<td>Cargo</td>
</tr>
<tr>
<td>---</td>
<td>--------------------------</td>
<td>---------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>10</td>
<td>Armando Gobeia</td>
<td>Hospital Central da Beira <em>Sofala</em></td>
<td>Médico, DTC Vice- Presidente</td>
</tr>
<tr>
<td>11</td>
<td>Armando Meque</td>
<td>Hospital Provincial de Pemba <em>Cabo Delgado</em></td>
<td>Director Clínico</td>
</tr>
<tr>
<td>12</td>
<td>Artur Luis</td>
<td>Hospital Central de Maputo</td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>13</td>
<td>Avone Chuquela</td>
<td>Direcção Nacional de Assistência Médica Maputo</td>
<td>Médica</td>
</tr>
<tr>
<td>14</td>
<td>Benedito Chaúque</td>
<td>USAID _Maputo</td>
<td>Consultora</td>
</tr>
<tr>
<td>15</td>
<td>Camila Breyer</td>
<td>SIAPS/MSH _Maputo</td>
<td>Consultora</td>
</tr>
<tr>
<td>16</td>
<td>Delto Jose Meneses</td>
<td>Hospital Provincial de Tete <em>Tete</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>17</td>
<td>Didon Olavo Cacheta</td>
<td>Hospital Provincial de Quelimane <em>Zambézia</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>18</td>
<td>Dr. Ussene Isse</td>
<td>Direcção Nacional de Assistência Médica Maputo</td>
<td>Médico</td>
</tr>
<tr>
<td>19</td>
<td>Elenia Azarias Macamo</td>
<td>Hospital Central de Nampula <em>Nampula</em></td>
<td>Director Clínico</td>
</tr>
<tr>
<td>20</td>
<td>Eugenia Munguambe</td>
<td>Hospital Central de Nampula <em>Nampula</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>21</td>
<td>Feliciano Cumaquela</td>
<td>Hospital Central de Maputo</td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>22</td>
<td>Fonseca Júlio Domingos</td>
<td>Hospital Central da Beira <em>Sofala</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>23</td>
<td>Gregorio Ernesto Gale</td>
<td>Hospital Provincial de Inhambane <em>Inhambane</em></td>
<td>Clínico</td>
</tr>
<tr>
<td>24</td>
<td>Helder Nhocuane</td>
<td>Hospital Provincial de Lichinga <em>Niassa</em></td>
<td>Director Clínico</td>
</tr>
<tr>
<td>25</td>
<td>Hélio Gemo</td>
<td>Departamento de Farmácia Hospitalar/DNAM/MISAU <em>Maputo</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>26</td>
<td>Horácio Lupanheque</td>
<td>Hospital Provincial de Lichinga <em>Niassa</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>27</td>
<td>Isabel Dinis Pinto</td>
<td>Direcção Nacional de Assistência Médica <em>Maputo</em></td>
<td>Bióloga</td>
</tr>
<tr>
<td>28</td>
<td>Jorge Aleluia Vicente</td>
<td>Hospital Provincial de Manica <em>Manica</em></td>
<td>Médico Cirurgião, Presidente do CHTF de Manica</td>
</tr>
<tr>
<td>29</td>
<td>Vânia Manhique</td>
<td>Hospital Provincial da Matola <em>Maputo</em></td>
<td>Médica</td>
</tr>
<tr>
<td>30</td>
<td>Júlio Langa</td>
<td>ICAP Inhambane_Inhambane</td>
<td>Assessor para a Área de Farmácia</td>
</tr>
<tr>
<td>31</td>
<td>Lidia Cunha</td>
<td>Hospital Provincial de Tete <em>Tete</em></td>
<td>Directora Clínica</td>
</tr>
<tr>
<td>32</td>
<td>Maria Helena Costa</td>
<td>Hospital Geral de Mavalane <em>Maputo</em></td>
<td>Director Clínico</td>
</tr>
<tr>
<td>33</td>
<td>Paula Tocha</td>
<td>Direcção Nacional de Assistência Médica <em>Maputo</em></td>
<td>Médica Dentista</td>
</tr>
<tr>
<td>34</td>
<td>Merana Mussá</td>
<td>Departamento Farmacêutico_Farmacovigilância <em>Maputo</em></td>
<td>Departamento Farmacêutico/Farmacovigilância</td>
</tr>
<tr>
<td>35</td>
<td>Narciso Cumbana</td>
<td>Hospital Geral de Mavalane <em>Maputo</em></td>
<td>Farmacêutico</td>
</tr>
<tr>
<td>36</td>
<td>Natacha Mbeve</td>
<td>Departamento de Farmácia</td>
<td>Assessor Técnica</td>
</tr>
<tr>
<td></td>
<td>Nome</td>
<td>Título</td>
<td>Departamento</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------</td>
<td>-------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>37</td>
<td>Neusa Bay</td>
<td>Sénior Farmacêutica</td>
<td>SIAPS/MSH_Maputo</td>
</tr>
<tr>
<td>38</td>
<td>Nuro Ali</td>
<td>Farmacêutico</td>
<td>Hospital Geral Jose Macamo_Maputo</td>
</tr>
<tr>
<td>39</td>
<td>Olga Novela</td>
<td>Médica</td>
<td>Direcção Nacional de Assistência Médica_Maputo</td>
</tr>
<tr>
<td>40</td>
<td>Paula Denise Pinto</td>
<td>Medica –DTC Vice-president</td>
<td>Hospital Geral José Macamo_Maputo</td>
</tr>
<tr>
<td>41</td>
<td>Paulo Carlos Vilanculos</td>
<td>Farmacêutico</td>
<td>Hospital Provincial de Pemba_Cabo Delgado</td>
</tr>
<tr>
<td>42</td>
<td>Randes Nafussa</td>
<td>Farmacêutico</td>
<td>Hospital Provincial da Matola_Maputo</td>
</tr>
<tr>
<td>43</td>
<td>Rafique Edson J. Bualani</td>
<td>Farmacêutico</td>
<td>Hospital Distrital de Mocuba_Zambézia – Mocuba</td>
</tr>
<tr>
<td>44</td>
<td>Sureia Hassamo</td>
<td>Assessora Técnica Sénior</td>
<td>Global Fund/MISAU_Maputo</td>
</tr>
<tr>
<td>45</td>
<td>Tânia Sitoi</td>
<td>Chefe do DFH</td>
<td>Departamento de Farmácia Hospitalar/DNAM/MISAU_Maputo</td>
</tr>
<tr>
<td>46</td>
<td>Tatiana Fonseca</td>
<td>Assessor para a Área de Farmácia</td>
<td>Centro de Colaboração em Saúde (CCS)_Maputo</td>
</tr>
<tr>
<td>47</td>
<td>Terry Green</td>
<td>Consultor</td>
<td>SIAPS/MSH_Maputo</td>
</tr>
<tr>
<td>48</td>
<td>Vicente Garcia</td>
<td>Tecnico de Medicina</td>
<td>Hospital Distrital de Mocuba_Zambézia – Mocuba</td>
</tr>
<tr>
<td>49</td>
<td>Virginia Albino</td>
<td>Medica</td>
<td>Hospital Provincial de Quelimane_Zambézia</td>
</tr>
<tr>
<td>50</td>
<td>Yolanda Cachomba</td>
<td>Director Clínico</td>
<td>Hospital Provincial de Xai-Xai_Gaza</td>
</tr>
<tr>
<td>51</td>
<td>Carmina Biquiza</td>
<td>Farmacêutica</td>
<td>Central de Medicamentos e Artigos Médicos_Maputo</td>
</tr>
<tr>
<td>52</td>
<td>Sergio Seni</td>
<td>Farmacêutico</td>
<td>Central de Medicamentos e Artigos Médicos_Maputo</td>
</tr>
<tr>
<td>53</td>
<td>Alginane I. Mussagy</td>
<td>Direcção Nacional da Assistência Médica Protocoilo</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Mayra Rodrigues</td>
<td>Direcção Nacional da Assistência Médica Protocoilo</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Juan Rumbero</td>
<td>Assessor</td>
<td>Direcção Nacional da Assistência Médica Protocoilo</td>
</tr>
<tr>
<td>56</td>
<td>Maria dos Anjos</td>
<td>Directora Clínica</td>
<td>Hospital Geral Polana Caniço</td>
</tr>
</tbody>
</table>
ANNEX C. PARTICIPANT PRESENTATIONS

1. Niassa Provincial Hospital CHTF-Lichinga

Findings
- The three most prescribed medicines are: antibiotics, analgesics and anti-malarial.
- Conducted a study on medical prescriptions in the outpatient pharmacy. The main problems encountered at the level of requirements were:
  - Prescriptions without the patient's age
  - Prescriptions with antibiotic association
  - Prescriptions with antimalarial and NSAIDS

Impact:
- Assist the services in the management of pharmaceutical medicines
- Ensure the rational use of medicines through the analysis of requirements and cardexes.

2. Cabo Delgado-Pemba Provincial hospital CHTF

Findings:
- The most prescribed medicines at the hospital level are: antibiotics, NSAID and Antimalarias

Study
  Conducted a study of evaluation of medical instructions

Results:
- 35% of prescriptions without patient's age
- 33% of prescriptions with antibiotic association
- 6% of prescriptions without code number of National Drug Formulary

Impact of the activities of the Committee
- Advise on support the pharmaceutical services in acquisition of medicines
- Ensure the rational use of medicines through the analysis of instructions and cardexes.

Existence of weak medicine rotation for: propranolol, digoxin, haloperidol, etc.
3. Nampula-Nampula Provincial Hospital CHTF

Study
Evaluated prescription indicators.

Results:

The 3 most prescribed medicines are analgesics, anti-inflammatories, antibiotics followed by anti-malarial.

Impact of the activities of the committee:
- Reducing the risks of diseases
- Reduction of the admission period or time (duration of admission)
- Reduction of dispensing prescription with more than 2 antibiotics
- Reduction of dispensing prescriptions without signature and stamp of prescriber

4. Zambézia-Quelimane CHTF Provincial Hospital

Study
The DTC conducted a study of hospital indicators on the use of antimicrobials in the outpatient and inpatient department.

Results:
- Improvement in the satisfaction level of services of orthopedics, surgery, pediatrics and medicine wards
- The medicines are prescribed by international non-proprietary name
- Decrease the exposure time of the antimicrobial patients
- Medicines of weak rotation: calcium gluconate, pyridoxine and heparin, etc.

5. Zambézia-CHTF of Mocuba Rural Hospital

Findings:
- There are medicines with low rotation such as thioridazine, fluphenazine, haloperidol, oral antidiabetic medicines, etc.
- Lack of National Drug Formulary in hospitals
- The acquisition of medicines is made according to the EML prepared at the level of the hospital

Impact of the activities of the Committee in the management of medicines
- Improvement on prescription mediciness
- Improvement in the management of medicines on medical wards
- Clinical cases of malaria reduction (reduction of people treated with antimalarial without positive malaria rapid test or smear)
6. Tete-Tete Provincial Hospital CHTF

Findings:
- Conducted a study of prescriptions
- Weak involvement of the directors of the services
- Lack of National Medicines Formulary on the level of the consultations

Impact of the activities of the Committee in the management of medications:
- Improvement in the management of medicines at hospital level
- Strengthening of the supervisory activities of the wards
- Increased number of Adverse Drug Reactions reported
- Creating groups to provide technical assistance to the wards

There are low rotation medicines such as: vitamin A, allopurinol, cycloserine, etc.

7. Manica-CHTF of Chimoio Provincial Hospital

Study
- A study of prescriptions with the following results:
  - 19.69% of prescriptions without Number of Patient Identification (NID), 16.12% of prescriptions without pharmaceutical form, 15.59% without dosage of medicine and 14.69% without age of patient.
  - Improvement in the reporting of adverse drug reactions.

Impact of the activities of the Committee in the management of medicines
- Improvement in the management of medicines.
- Improvement in communication between clinicians, pharmacy staff and patients.

Other issues
- Lack of prescriptions forms at hospital level, use of khaki paper to write prescriptions
- Lack of STGs
- Lack of nutritionists at hospital level
- Need to work with national Pharmacovigilance programs to implement a comprehensive programs at the DTC
- Need for a nutritionists at the DTC
- Laboratories with weak responsiveness in the diagnosis of pathologies.
- There are medicines of weak rotation such as: simvastatin, heparin, ethionamide, etc.
- Need for integration of pharmacy staff on the medical wards
8. Sofala-CHTF Provincial Hospital of Beira

Findings
- Lack of orientation guide of hospital pharmacy and a hospital medicines policy
- Lack of specific training on rational medicine use for committee members
- Lack of pharmacologist in the DTC
- There are medicines of weak rotation: sulfadiazine, propranolol, maprotiline, etc.
- Therapeutic protocols or STGs developed at the level of hospitals are sent to central level for uniformity

9. Inhambane Provincial Hospital CHTF Inhambane

Impact of the activities carried out by the committee in the management of medicines
According to the committee, it is premature to assess the impact of the activity on the management component of medicines and medical supplies since the activity is still ongoing.

There are medicines of weak rotation such as omeprazole injectable, ferrous sulfate, tetracycline capsules, etc.

10. Gaza-CHTF Provincial Hospital of Xai-Xai

Impact of the activities of the Committee in the management of medicines
- Good coordination of pharmacy with clinicians and DPM
- Reducing stock-outs of essential medicines

There are medicines of weak rotation such as: cefixime, nifedipine, atenolol, etc.

Results of the study of medical prescriptions
- Reduction in prescribing antibiotics associated with anti-malarial and reduction of prescriptions containing more than 3 medicines

11. Maputo Mavalane General Hospital- Mavalane

Study
Achievements of study on quality of prescription:
- The study concluded that prescriptions have lack of information about the health facility, no stamp of the prescriber and signature of pharmacist.
- 29.5% of prescriptions were not legible
- 31.5% of prescription did not present the duration of the treatment.
General Recommendations

1. It is important that all committees carry out studies of medicine use and management. In the next national meeting of CHTFs they should present the results of the studies carried out in the hospitals.

2. It is important to standardize the techniques for improvement of diagnostic results.

3. Improve communication between the committees.

4. Adopt a mechanism of control of medicines in pharmacies.

5. Change the tendency of hospital prescription habits.

6. The Committee should make strict monitoring of activities in health facilities for the smooth running of the same.

7. It is important to review the prescription levels in order to correct current practices taking into account the current situation of lack of human resources.

8. Each hospital should have a list of essential needs in terms of medicines according to the level of its health facility (primary, secondary, tertiary and quaternary).

9. Inclusion of nutritionists and laboratory technicians in the committee and send the list of members to DFH.

10. All therapeutic protocols developed by clinicians at provincial level should be sent to the Department of Hospital Pharmacy for uniformity and subsequent approval. Note: all authors will appear in the list of authors.

11. Improve communication between the provinces through the central level to improve the management of medicine of low rotation.

12. Improve the distribution and allocation of the Pharmacy staff at provincial level in order to answer the needs of Health Facilities.

13. Carry out activities to train pharmacy professionals in clinical pharmacy.

Recommendations (Manica)

Proposes to create mechanisms for interaction or communication between hospitals to make a return of medicines with low turnover in order to improve the management of these medicines.

Equip the laboratories in order to make the rapid diagnosis and improve the use of antibiotics.
SYNTHESIS of DAY 2 – August 5, 2014

Presentations of the group work on medicine use problems and potential solutions.

**Group I**

<table>
<thead>
<tr>
<th>Problems identified</th>
<th>Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irregular distribution of medicines</td>
<td></td>
</tr>
<tr>
<td>Poor quality of material (prescriptions forms, etc)</td>
<td></td>
</tr>
<tr>
<td>Failure in the supply of medicines</td>
<td></td>
</tr>
<tr>
<td>Lack of communication among professionals</td>
<td></td>
</tr>
<tr>
<td>Lack of pharmaceutical attention</td>
<td></td>
</tr>
<tr>
<td>Lack of consumer data submission</td>
<td></td>
</tr>
<tr>
<td>Bad planning of infrastructures</td>
<td></td>
</tr>
</tbody>
</table>

**Group II**

<table>
<thead>
<tr>
<th>Problems identified</th>
<th>Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unavailability of essential medicines</td>
<td>Periodic review of National Formulary, where various experts must participate</td>
</tr>
<tr>
<td>Non-updated therapeutic protocols</td>
<td>Improving the system of periodic review/information of standard treatment protocols</td>
</tr>
<tr>
<td>Lack of harmonization of different programs</td>
<td>Improve communication between the managers of the different programs</td>
</tr>
<tr>
<td>Prescription of mediciness without proper diagnosis</td>
<td>Improve the use of diagnostic tests</td>
</tr>
<tr>
<td>Prescription with unreadable handwriting, missing elements in the prescription</td>
<td>Awareness of prescribers to change their prescription behavior</td>
</tr>
<tr>
<td>Use of trade names</td>
<td>Correction by the Directorate</td>
</tr>
<tr>
<td>Low quality of pharmaceutical care to the patient</td>
<td>Improve academic training</td>
</tr>
<tr>
<td>Poor treatment adherence</td>
<td></td>
</tr>
<tr>
<td>Self-medication</td>
<td></td>
</tr>
<tr>
<td>Poor conservation of medicines</td>
<td></td>
</tr>
</tbody>
</table>

**Group III**

<table>
<thead>
<tr>
<th>Problem</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irregular availability of Medicines</td>
<td>Definition of essential medicines to the NHS</td>
</tr>
<tr>
<td>Difficulties in management</td>
<td>Review the cost of the medicine</td>
</tr>
<tr>
<td></td>
<td>Improve the management of medicines</td>
</tr>
<tr>
<td></td>
<td>Training on the job.</td>
</tr>
<tr>
<td>Irregular and inappropriate self-medication administration (Adherence to the treatment)</td>
<td>Improve patient communication at all levels</td>
</tr>
<tr>
<td>Habit of prescribing the same medicine</td>
<td>Training in work (medical education)</td>
</tr>
<tr>
<td>Poor writing or unreadable medicine</td>
<td>Allocate quality human resources</td>
</tr>
<tr>
<td>Greater waiting time</td>
<td></td>
</tr>
<tr>
<td>Misinterpretation of the prescription</td>
<td>Human resources allocation</td>
</tr>
<tr>
<td>Lack of accountability of the recipe</td>
<td>Opening more pharmacies</td>
</tr>
<tr>
<td>Greater waiting time</td>
<td></td>
</tr>
</tbody>
</table>
Group IV

<table>
<thead>
<tr>
<th>Problems identified</th>
<th>Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor communication between professionals in the central deposits with suppliers and quality control</td>
<td>Review and update stock and shipping to the province</td>
</tr>
<tr>
<td>Dispensing of medicines with short expiration date</td>
<td></td>
</tr>
<tr>
<td>Lack of satisfaction in dispensing</td>
<td></td>
</tr>
<tr>
<td>Poor communication between doctor and patients</td>
<td>Continuous training, access rules for prescribing and improve readability on medical prescription</td>
</tr>
<tr>
<td>Use of commercial names in the prescriptions</td>
<td></td>
</tr>
<tr>
<td>Ineligibility of prescription</td>
<td></td>
</tr>
<tr>
<td>Lack of communication with the patient</td>
<td>Training in new procedures in management, training continues and training of dispensers in the area of pharmaceutical care.</td>
</tr>
<tr>
<td>The absence of pharmaceutical care</td>
<td></td>
</tr>
<tr>
<td>Lack of human resources</td>
<td>Education for health in the communities, information about the disease to</td>
</tr>
</tbody>
</table>

Discussion

- Non-participation of pharmacy professionals in co-management committees meetings and humanization communities
- Lack of attention to dosage in the moment of dispensing medicines to patients
- Lack of training continues
- Lack Pharmaceutical Directorate services at the hospital level
- Lack a list containing the name and signature of all prescribers in pharmacy

Recommendation

- Include Pharmacy professionals in quality and humanization committees.
- Creating a list of prescribers to outpatient level as well as the inpatient level. This list should be available in pharmacies.
- The committees are responsible for the identification of problems and its resolution. Improvement on the advice of the medicines to patients.
- The committees should invite other key members in some areas (tuberculosis, HIV, maternal and child health, immunization program) to participate in their meetings to discuss some activities.
- The committees can improve the relationship between the different health professionals for its multidisciplinary character.
- The National Drug Formulary should be reviewed.
- There must be a greater communication with the Central level (DFH).
- Experts should be included in the development of essential medicine list.

Functions and key activities of the committees

- Development of EML
- Assessment criteria of use of medicines
- Identify the problems of medicines, making indicators studies, evaluation of use of medicines etc.
- Monitoring and evaluation of the Committee performance to improve the efficiency in the activities undertaken.
- Monitor the Adverse Drug Reactions at health facilities
ANNEX D. RECOMMENDATIONS AND NEXT STEPS

Each DTC will work on the following activities over the next year (with support from MISAU and SIAPS)

DTC Structure and functions

- All DTCs must have approvals from Hospital Director
- Implement TOR at each facility (available from MISAU)
- Develop action plans and objectives for the year
- Ensure DTC has appropriate members, ones that will empower the DTC to achieve its objectives of improving medicine use at all levels of the healthcare system

STGs

- Obtain all approved MISAU Guidelines for hospitals and health facility and make sure they are readily available for the health care staff. Need 1 copy to each provider
- Provide training on use of STGs, especially new staff
- Study and monitor 1 or 2 important medical conditions (e.g., HIV, Malaria, Hypertension) for compliance to guidelines. Include a baseline of current practices. SIAPS will support the implementation of these studies

EML

- Study and monitor medicine use against the approved EML, determine % of prescriptions in accordance with approved EML
- Provide feedback to providers on compliance
- When revised EML becomes available – implement ASAP
- Need current national formulary and essential medicines list to be provided to health facilities

Medicine Use Evaluation (MUE)

- Potential MUE depending local circumstances
  - Surgical prophylaxis (C-section)
  - High profile medicine (e.g., Antiretroviral, gentamicin, ceftriaxone)

Other Possible Activities

Address Supply Management issues - work with MISAU, warehouse, and DTC to improve the supply management at the hospital or clinic

Medicine use study (if time and staff available)

- Conduct WHO Health facility indicator study, specifically % of antibiotics, % generic name, average number drugs / prescription.
- Conduct MSH Hospital Antimicrobial indicator studies for selected hospitals.
ANNEX E. STANDARD TREATMENT GUIDELINE MEDICINE USE EVALUATION PROTOCOL

Medicine Use Evaluation
Mozambique Standard Treatment Guidelines

August 25, 2014

Background

Standard Treatment Guidelines (STGs) are one of the key World Health Organization (WHO) recommendations to rationalize the use of medicines. The use in healthcare settings worldwide produce benefits for health system, health professionals, and patients.

Health Systems

- Provides information for forecasting and ordering
- Provides effective therapy in terms of quality
- Provides a system for controlling costs
- Provides information for practitioners to give to patients concerning the institution’s standards of care
- Serves to integrate special programs (HIV/AIDS, diarrhea disease control, TB) at the primary health care center with a single set of guidelines

Health Professionals

- Provides standardized and approved guidance to practitioners.
- Promotes high quality care by directing practitioners to the most appropriate medicines for specific conditions
- practitioners can concentrate on diagnosis knowing that the appropriate medicines are listed and available, evidenced-based treatments have been established
- Provides assistance to all practitioners, especially to those with lower skill levels

Patients

- Patients receive optimal pharmaceutical therapy and the highest quality of care
- Enables consistent and predictable treatment and access to effective medicines and best treatment available
- Provides a basis for evaluating quality of care provided by health care professionals

MISAU has produced significant effort to improve the use medicines in Mozambique, one of the key activities is the development of STGs for a limited set of diseases. STGs exist for infectious diseases of HIV/AIDS, Malaria, Tuberculosis, STI, and some chronic diseases including hypertension and diabetes. MISAU is in progress of developing other STGs for prevalent diseases and these should be completed in the near future.
For this STG medicine use evaluation, the highly prevalent diseases of HIV/AIDS, malaria, and hypertension were selected to review for appropriate compliance to the approved STGs. These diseases and STGs were selected because they have high impact on adults and children quality of care. Rationale includes:

- HIV/AIDS and related diseases are a major cause of mortality among children in Mozambique. In 2010, it is estimated that 19,000 children under the age of 15 will die as a result of the disease (Source: UNICEF Mozambique).

- In Mozambique, malaria is a major cause of morbidity and mortality especially among children. The disease represents around 45% of all cases in outpatient visits, approximately 56% of inpatient at pediatric clinics and around 26% of all hospital deaths. According to the Demographic Health Survey 2011, the prevalence of malaria among children under five years is 46.3% in rural areas compared to 16.8% in urban areas. The relatively high prevalence in many parts of the country puts the entire population at risk and poses a challenge for malaria elimination efforts nationally and in neighboring countries.

- Cardiovascular diseases are the 4th leading cause of death in Mozambique. One in every three Mozambicans’ has hypertension – a major risk factor for stroke. In Maputo City alone, 2-3 strokes occur every day with a mortality rate of 40% (source: WHO 2014)

Having a STG doesn’t mean there is automatic improvement in medicine use. Many factors can influence the use of STGs and lead to misuse. The availability of the guideline, training on use of the guideline, and actual use in day to day practice can all vary from one location to another. Taking this into account, it is important to know how they are used in the health facilities and what factors contribute to their use. Without consistent use, the STGs are of little value.

**Purpose**

To assess the use of STGs in three diseases; HIV/AIDS, malaria, and hypertension and ensure appropriate availability and high compliance with the guideline.

**Objectives of the Assessment**

1. To determine the degree of compliance with the Mozambique STGs for 3 medical conditions: HIV/AIDS, malaria, and hypertension.

2. To explore factors influencing compliance and availability of the STGs in selected hospitals.

3. To determine the need for specific interventions to improve compliance to STGs.

4. To intervene with appropriate intervention and ensure compliance with the guidelines at a level of 90% or higher.
Methodology

A retrospective review will be conducted at four hospitals in Maputo and 3 additional sites in outlying provinces. The data collection will be carried out by local DTC members under the supervision of MISAU (Hospital Pharmacy Department) and Systems for Improved Access to Pharmaceuticals and Services (SIAPS). The specific hospitals were chosen, based on:

- location - Maputo and provinces representing a northern province, a central province, and a southern province
- need to confirm compliance with standards
- availability of a local DTC to manage:
  - the data collection
  - follow-up monitoring
  - actions including introductions of medicine use interventions to strengthen the compliance on STG if needed.

Facilities to be reviewed:
Maputo
- Maputo Central Hospital
- Jose Macamo General Hospital
- Mavalane General Hospital
- Matola Provincial hospital

Provincial Health Facilities
- Inhambane Provincial Hospital (Inhambane Province)
- Quelimane Provincial Hospital (Zambézia Province)
- Nampula Provincial Hospital (Nampula Province)

Initially, one health facility will be selected to start this MUE. After initial assessment, introduction of interventions and the establishment of improvement and reaching targets, other hospitals will be added.

Data collectors will review medical records, registries and prescription to obtain the necessary quantitative data for the review (see Annex A). A second survey instrument, interview of physicians and pharmacists, will document the reasons for using or not using the STGs. A third instrument, health director/clinical director interview form (annex C) will be used to determine health facility participation in the use of STGs.

The sample size will consist of 30 medical records (randomly selected from records over the past 12 months for malaria and hypertension diseases. For HIV/AIDS, the previous 4 months will be used because the HIV/AIDS protocol was recently revised and disseminated in May 2014.
Prescriptions for the selected disease conditions will be reviewed from the patient medical records or registries. Information will be recorded on data collection tool (annex A) and will be analyzed for compliance with the STG exactly as written in these approved STGs.

**Data Collection Procedure**

Data will be collected over a two day period for each disease state, after confirming approval for the activity from the hospital director, data collectors will review necessary medical records and registries and collect the necessary information on data collection instrument (See Annex D for details of procedure). For some of the hospitals, interviews of providers and health officials will take place in the week before the review by members of the hospital DTC.

**Data Collection Team(s)**

To build capacity in the regions, data collection will be conducted by hospital DTCs and supervised by MISAU and SIAPS.

**Data Collection Tools**

Annex A contains a data collection tool used to record information from the patients’ health record. The instrument enables the treatment prescribed to be compared against treatment recommended by the current STGs for each of the tracer disease conditions selected.

Annex B is the tool used to collect qualitative data from prescribers. The prescribers interviewed were selected from among prescribers in the outpatient department at the same health facilities from which the data on prescriptions were obtained.

Annex C – has an instrument to interview hospital and primary health officials on the availability and use of STGs.

**Selection Criteria for Prescriptions**

**Inclusion**

Only prescriptions generated between October 2013 to September 2014 by prescribers at the health facilities with the diagnosis of HIV/AIDS, malaria, or hypertension were included in the assessment. If there were two or more prescriptions for the same condition in the medical record, any one of the eligible prescriptions written during the study period will be selected. Prescriptions were attributed to the person who signed the prescription on the date of treatment, e.g., if it was a repeat prescription prepared by a nurse for a prescription that was originally written by a doctor, it was attributed to the nurse.

**Exclusion**
The following exclusion criteria were applied to the prescriptions during the data collection process:

- Prescriptions without a diagnosis or with an unclear diagnosis.
- Prescriptions with an unclear prescriber, i.e., where it was not clear whether the prescriber was a doctor, nurse, etc.
- Prescriptions prepared outside the study period

**Outcome Measures**

The outcome measures for the assessment were developed in line with the assessment objectives

1. % of medicines prescribed in accordance with STG
2. % of medicines prescribed by generic name
3. % of prescriptions with unnecessary medicines
4. % of health facilities with a copy of the guideline in treatment area and readily available for practitioners
5. % of health professionals with a personal copy of the guideline
6. % of qualified prescribers for each medical condition reviewed

Overall outcome: Pharmaceutical Services improved.

**Data Entry and Analysis**

Data will be recorded on data collection instruments (annex A) and this information will be transferred to Excel spreadsheet designed to record data collection and calculate the indicators. All data recorded will be exactly as written in the medical record and analysis will compare exactly as written in the MISAU approved standard treatment guidelines.

A spreadsheet designed this activity will be utilized to document results of the survey, analyze results, and calculate indicators. SIAPS and MISAU will be responsible for data cleaning and final data analysis and reporting. Results will be report to DTCs and MISAU.

**Follow-up and implementation of Interventions**

Depending on the results, specific interventions will be introduced at each hospital to improve compliance including the use of education (in-service training, face to face education), managerial (supervision, order sheets, job aids) as necessary. Interventions will be introduced and monitoring of the use of the STG will take place on a continuous basis until targets are reached, e.g., 90% compliance.
**Technical review of protocol**

This protocol for collecting and analyzing data and the entire assessment process will be reviewed by SIAPS technical staff in Arlington, VA, senior technical staff and hospital pharmacy department, MISAU.

References:

WHO, How to Investigate Drug Use in Health Facilities: Selected Indicators, 1993 World Health Organization

(STG Protocol - Annex A. Data Collection Instrument)

<table>
<thead>
<tr>
<th>Medical record #</th>
<th>Date of data collection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data Collector</th>
<th>Date of prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health Facility Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Health Facility Region</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Position of prescriber</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physician</th>
<th>Nurse</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient’s weight</th>
<th>Patient’s birthday -</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary diagnosis indicated on medical record</th>
<th>Other diagnosis recorded</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signs and symptoms listed in medical record</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory tests done</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment Prescribed (exactly as prescriber has written)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#</th>
<th>Medicine (1)</th>
<th>Dose and Frequency (2)</th>
<th>Duration (3)</th>
<th>Generic (4) Y-1 N-0</th>
<th>Antibiotic (5) Y-1 N-2</th>
<th>Compliance with STG (exactly as written) (if No, indicate which parameter with STG)</th>
<th>Compliant with STG (Y-1)</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other comments/observations for this patient’s treatment</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Akpabio, E, et al
**Introduction and Consent**

Hello, I am ........................................ part of the data collection team from MISAU and your DTC team to assess the implementation of the Standard Treatment Guidelines in public facilities (HIV/AIDS, malaria, and hypertension). This assessment is being carried in 7 hospitals in Mozambique. The findings of this assessment will help to improve the quality of medicine use and health care in Mozambique.

As a prescriber in this facility, you are highly regarded as a key respondent for this assessment. You are kindly requested to give honest information for purposes of genuine and accurate results.

**Procedures and Confidentiality**

Your participation is absolutely voluntary and there is no penalty for refusing to take part. All information that I record will be kept strictly confidential; your name will not be used and you will not be identified in any way.

**Risks/discomfort and Benefits:**

There is no serious risk to you if you agree to participate in this activity. Your honest opinion will help in developing interventions to improve use of STG to improve patient care in Mozambique.

**Consent to participate**

I have read (or someone has read to me) and I have understood the information given above and what will be required of me if I choose to take part in the assessment. I therefore agree to take part in this study

Signature of respondent: ........................................ Date: ..............................

Interviewer Name: ........................................

Thank you for accepting to take part in this assessment.

**Questionnaire**

Have you ever seen a copy of the Mozambique Standard Treatment Guidelines (HIV, Malaria, Hypertension)?

(1) □ YES  (2) □ NO  List the ones seen:

Have you ever received a personal copy of the STG?

(1) □ YES  (2) □ NO  List ones that they have a personal copy

Do you currently have access to a copy of the STG when you need it?

(1) □ YES  (2) □ NO

How often do you make reference to the guidelines (STGs)?

(1) □ Daily  (2) □ Once in a week  (3) □ Once in a month  (4) □ Once in 6 months  (5) □ rarely

(6) □ Never  (7) □ Other (state explicitly) ...........................................
Could you explain more what makes you use the STG on the frequency you have stated?

In your experience is the current STGs helpful in your prescribing practices?
   (1) □ YES  (2) □ NO

Could you explain more what makes it helpful/not helpful in your prescribing practices?

How do you rate the quality of the current STGs in the following parameters?

Comprehensiveness in conditions covered
   □ Very poor  □ Poor  □ Fair  □ Good  □ Very good  □ Don’t know

Quality of design and layout
   □ Very poor  □ Poor  □ Fair  □ Good  □ Very good  □ Don’t know

User friendliness
   □ Very poor  □ Poor  □ Fair  □ Good  □ Very good  □ Don’t know

Do you think the current Mozambique STG is up to date?
   (1) □ YES  (2) □ NO

Do you think the current Mozambique STG needs improvement?
   (1) □ YES  (2) □ NO

If YES above, what do you think should be done to improve on the current STGs?

□ In-service training on STGs
□ Monitoring on use of the new STGs
□ Facility level medicine use evaluations
□ Awareness creation on STGs

□ Awareness creation on STGs
(1) □ YES  (2) □ NO  Other

intervention since the launch (Specify):  

□ NO INTERVENTION

Have you participated in any of the following interventions related to STGs since the launch in 2011? (Tick all options that apply)

□ In-service training on STGs
□ Monitoring on use of the new STGs
□ Facility level medicine use evaluations
□ Awareness creation on STGs

Other intervention since the launch (Specify):  □ Not participated in any intervention

Adapted from Akpabio, E, et al
(STG Protocol, Annex C. Interview form for Health Officials at Hospitals and Clinics)

Interview form for health officials at Hospitals and Clinics

<table>
<thead>
<tr>
<th>Health Facility</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>Health Official Interviewed</td>
<td></td>
</tr>
<tr>
<td>Position</td>
<td></td>
</tr>
<tr>
<td>Interviewer</td>
<td></td>
</tr>
</tbody>
</table>

**Introduction and Consent**

Hello, I am ........................., part of the data collection team from MISAU and your DTC team to assess the implementation of the Standard Treatment Guidelines in public facilities (HIV/AIDS, malaria, and hypertension). This assessment is being carried in 7 hospitals in Mozambique. The findings of this assessment will help to improve the quality of medicine use and health care in Mozambique.

As a prescriber in this facility, you are highly regarded as a key respondent for this assessment. You are kindly requested to give honest information for purposes of genuine and accurate results.

**Procedures and Confidentiality**

Your participation is absolutely voluntary and there is no penalty for refusing to take part. All information that I record will be kept strictly confidential; your name will not be used and you will not be identified in any way.

**Risks/discomfort and Benefits:**

There is no serious risk to you if you agree to participate in this activity. Your honest opinion will help in developing interventions to improve use of STG to improve patient care in Mozambique.

**Consent to participate**

I have read (or someone has read to me) and I have understood the information given above and what will be required of me if I choose to take part in the assessment. I therefore agree to take part in this study

.................................................. .............................. Signature of respondent   Date

Interviewer Name:

Thank you for accepting to take part in this assessment.

**Questionnaire**

Have you ever seen a copy of the HIV/AIDS, Malaria, or Hypertension Standard Treatment Guidelines ((STG))?

(1) □ YES  (2) □ NO  List ones you have seen

Did your receive copies of the STGs for each health facility in your region/ district since they were made available?

(1) □ YES  (2) □ NO

What interventions have been conducted by this health facility since the launch of the
STGs to ensure its availability and use by prescribers? *(Tick all options that apply)*

<table>
<thead>
<tr>
<th>Name of intervention</th>
<th>Carried Out (Y/N)</th>
<th>How Often Carried Out</th>
<th>114. Any documentation available? (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Distribution of STG to all health facilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. In-service training on STGs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Monitoring on use of the new STGs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Facility level medicine use evaluations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Awareness creation on STGs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Other intervention since the launch <em>(Specify)</em>:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Do you think all prescribers have access to the STGs in your District?

☐ Yes ☐ No

If no, could you explain why this is so?

Do you think the current Mozambique STGs are up to date? …………… (1) ☐ YES  (2) ☐ NO

What do you think should be done to improve on the current STG?

a) Increase number of health conditions covered  (1) ☐ YES  (2) ☐ NO  (3) Don’t Know

b) Reduce number of health conditions covered  (1) ☐ YES  (2) ☐ NO  3) Don’t Know

c) Develop new sections  (1) ☐ YES  (2) ☐ NO  (3) Don’t Know

d) Improve quality of paper  (1) ☐ YES  (2) ☐ NO  (3) Don’t Know

e) Improve design  (1) ☐ YES  (2) ☐ NO  (3) Don’t Know

f) Improve graphics and charts  (1) ☐ YES  (2) ☐ NO  (3) Don’t Know

g) Other suggestions: ..................................................................................

h) No improvement needed …..(1)

☐ Yes
Annex E

What do you think are the barriers to the use of the Standard Treatment Guidelines by prescribers? *Please advise on how to overcome them*

<table>
<thead>
<tr>
<th>Barrier</th>
<th>Suggestions to overcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td></td>
</tr>
</tbody>
</table>

*Adapted from Akpabio, E, et al*
(STG Protocol, Annex D – Procedures for Data Collection)

1) **Formation of the data Collection Team(s):** Data collection will be led and coordinated by MISAU, Department of Hospital Pharmacy, SIAPS, and assisted by members of each hospital DTC in the respective health facilities. The team will attend a one day meeting in Maputo to review the data collection tools and logistics.

2) **Time frame for collection:** The data collection period will be for a period of 2 days for each health facility.

3) **Data Collection tools:** For each facility, data collectors will be provided with Instrument A, Data collection form, and 1 each of Instruments B and C for structured interviews.

4) **Data collection: Appendix A- Prescribing Practices**

Patient medical records (or outpatient registers in PHC Clinics) will be used to collect data onto the survey tool (Appendix A) for all the conditions.

In PHC Clinics the outpatient registers may be used as alternative or additional source of treatment data where the patient passports are not available for review.

Patients’ medical records will first be reviewed for any diagnosis for the 3 selected conditions; only prescriptions with dates in the first period August 2013 to September 1, 2014, will be selected. For HIV/AIDS, the time period will be from June 1, 2014 to September 30, 2014.

30 prescriptions should be randomly selected for each of the 3 conditions.

Information from the prescription will be transcribed from the medical records or register onto the survey tool (Appendix A)

If there are two or more prescriptions for the same condition in the record, *any one* of the eligible prescriptions falling in the study period will be selected. As much as possible, only one prescribing encounter per medical record will be used i.e. if a record contains prescribing encounters for three of the conditions to be assessed, just one of the conditions will be selected and data will be abstracted for that condition onto the data collection tool.

Prescriptions will be attributed to the person who signed the prescription on the date of treatment, e.g. if it is a repeat prescription by a nurse for a prescription that was originally done by a doctor, it will be attributed to the nurse.

5) **Data collection: Appendix B- Prescriber Interviews**

The prescriber interviews will be done after completion of data collection for Appendix A.

Appointments will be made with the respective prescribers to be interviewed

All the information collected will be entered into the questionnaire as required.

10 prescribers will be interviewed from each health facility
6) Data collection: Appendix C- Key Informant Interviews

Hospital directors and/or clinical directors will be interviewed to ensure access and use of the STGs by the prescribers since the STGs were made available.

7) Data entry procedures

Data will be entered into Instrument A exactly as it appears on the medical records or registry.

Data from Instrument A will subsequently be entered into spreadsheet specifically designed for recording information about the STG and for analyzing and calculating indicators.

Adapted Akpabio, E, et al.
### ANNEX F. DTC WORKSHOP EVALUATION

#### Workshop Evaluation Summary (Q1 to Q6 and Q8 to Q11) - in %

<table>
<thead>
<tr>
<th>Statement</th>
<th>Totally Agree</th>
<th>Agree</th>
<th>Disagree</th>
<th>Totally Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>The length of training were ideal</td>
<td>25.81</td>
<td>58.06</td>
<td>9.68</td>
<td>6.45</td>
</tr>
<tr>
<td>Materials provided were useful</td>
<td>45.16</td>
<td>51.61</td>
<td>2.23</td>
<td></td>
</tr>
<tr>
<td>The type and the format of the sessions were good</td>
<td>48.39</td>
<td>51.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The facilities where the training happened was good</td>
<td>51.61</td>
<td>45.16</td>
<td>3.23</td>
<td></td>
</tr>
<tr>
<td>The information received in this training will be useful in my work on a daily basis</td>
<td>83.87</td>
<td></td>
<td>16.13</td>
<td></td>
</tr>
<tr>
<td>The topics covered in these 2 days have focused on all important matters related to the rational use of Medicine and Therapeutic committees</td>
<td>51.61</td>
<td>48.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The topics covered in these 2 days were enlightening</td>
<td>51.61</td>
<td>48.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The topics covered in these 2 days were relevant</td>
<td>74.19</td>
<td></td>
<td>25.81</td>
<td></td>
</tr>
<tr>
<td>The objectives defined were achieved at the end of the program</td>
<td>54.84</td>
<td>45.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The goals were clearly defined at the beginning of the program</td>
<td>61.29</td>
<td></td>
<td>38.71</td>
<td></td>
</tr>
</tbody>
</table>
## Workshop Evaluation Participant Comments

<table>
<thead>
<tr>
<th></th>
<th>Q12 - Please give us your recommendations to improve the program in the upcoming opportunities:</th>
<th>Q13 – What other subjects or aspects should be addressed?</th>
<th>Q14 - Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The Seminar should take 3-4 days</td>
<td>Evaluate problems related the use of medicines used in specialties.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Create recommendations for the provincial superiors to give more power to the CHTF/DTCs</td>
<td>The Pharmacy staff should prepare for clinicians presentation regarding the slow rotation medicines to revitalize its use.</td>
<td>Reinforce the management of medicines on the economic politics</td>
</tr>
<tr>
<td>3</td>
<td>DNAM must press the Clinical Directors to reinforce the participation of the Clinical Directors in the DTC meetings.</td>
<td>Improve the time that the participants will stay in Maputo and congratulate the team that organized the seminar</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Improve subsistence allowances for participants</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Presentations in English with interpreters are tiring and participants lose concentration</td>
<td>Learned a lot and will try to implement in the field</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Can't understand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>The Seminar was excellent. Keep supporting the provinces</td>
<td></td>
<td>More attention should be given to phamacoeconomics and the presentations should be more clear</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>8</strong></td>
<td>Congratulations to the organizers, improve the disclosure of the seminar, propose to do the seminar out of the Maputo City</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>9</strong></td>
<td>The seminar was excellent</td>
<td>Keep the seminar annually</td>
<td></td>
</tr>
<tr>
<td><strong>10</strong></td>
<td>Always remember that food and medicine use the same path and the DTC trainings should have the compound of Nutrition. Mozambican population needs to improve their caloric intake, especially on the metabolic pathologies and the pharmacists should be aware of this.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11</strong></td>
<td>Involvement of other members of the DTC in the national workshop and send the invitation letter with enough time</td>
<td>Create a study and evaluate risk of the final destination of the medicines kept at home by the patients</td>
<td></td>
</tr>
<tr>
<td><strong>12</strong></td>
<td>Improve communications between the members of the DTC and between the DTCs and DNAM</td>
<td>The themes in the program of the workshop are the more important ones</td>
<td></td>
</tr>
<tr>
<td><strong>13</strong></td>
<td>Improve communications between the DTCs and the programs</td>
<td>Improve communications between the DTC and the other committees in all the country</td>
<td></td>
</tr>
<tr>
<td><strong>14</strong></td>
<td>Include one Laboratory staff to be represented in the DTC</td>
<td>There should be more visits to the DTCs at their local of work.</td>
<td></td>
</tr>
<tr>
<td><strong>15</strong></td>
<td>The seminar was very good, with a lot of interaction, very important to all</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16</strong></td>
<td>There should be more days for the Workshop to allow DTCs to present fully the activities of the committee</td>
<td>In RDU, should discuss the influence of the cycle of medicinedistribution in the country</td>
<td></td>
</tr>
<tr>
<td><strong>17</strong></td>
<td>Congratulate the initiative. This type of event should happened more frequently to harmonize the medicine management system from Rovuma to Maputo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>The invitation letter for the seminar should be sent earlier to allow the participants to prepare properly for the seminar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>There should be more discussions about pharmacovigilance</td>
<td>Increase the per diem</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>The per diem doesn’t match with Maputo City reality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>There should be more days for the Workshop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>The workshop should have more time for the presentation of studies</td>
<td>Speak more about pharmacovigilance and medicine management at the provincial level</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Send the invitation letter for the participants with more time in advance and request their confirmation with enough time in advance</td>
<td>Address the existing resources for the movement of the committee members to monitor the activities of the different areas</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>The workshop should have more days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Some of the presentation were a repetition from the previous DTC workshop</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ANNEX G. INTERVENTION REPORT FOR PILOT HOSPITALS,
Matola Provincial Hospital

Present at the meeting:

Dr. Lisa Malombe - General Director of the Hospital
Dr. José Sousa - Clinical Director of the Hospital
Dra. Durate Ibraimo – Medical doctor at Hospital
Randes Natussa – Head of the Pharmaceutical Services of the Hospital
Dr. Hélio Gemo – Department of Hospital Pharmacy/MISAU
Dr. Aminofro Langa - Department of Hospital Pharmacy/MISAU
Dr. Neusa Bay – SIAPS MSH
Dr. Terry Green – International Consultant
Dr. Alda Mariano – National Consultant

Objective: to determine what assistance is needed for Matola Provincial Hospital to start their DTC and what specific studies and interventions should be addressed.

Discussion

Dr. Helio Gemo presented the Department Hospital Pharmacy team and the objectives of the meeting. Dr José Sousa, clinical director, provided information on this hospital, a 400 bed provincial hospital that was opened in July 2014. They have many medicine use problems, mainly related to the fact that it is a new hospital and the Provincial Warehouse of Medicines is not prepared (and they don’t have a plan) to distribute medicines to hospitals. They have experience to distribute medicines to health centers and the mechanism of distribution is different. Now they are trying to obtain permission from MISAU to be supplied directly from the Central Medical Store, but do not know if it will work because policies say that this hospital should be supplied by the provincial warehouse.

This supply management problem is producing significant shortages of essential medicines including ARV and TB medicines, particularly 4DFC (a fixed dose combination containing rifampicin, isoniazid, pyrazinamide and ethambutol), from the warehouse because it is a hospital and the provincial warehouse is to supply only health centers. This hospital has many AIDS and TB patients admitted who have to interrupt their treatment during their admission.

Another crucial supply issue is the lack of oxygen for this new hospital. The hospital has an intensive care unit, recovery rooms, 4 operating rooms that all require oxygen and they have none. Obtaining enough oxygen and having it readily available has delayed the use of surgical department and ICU.

A DTC needs to be created to help manage some of the medicine use problems including the issues of availability. The DTC should be multidisciplinary in its membership as they have many different prescribers from different medical schools and countries.
Prominent diseases and medical conditions at the hospital include HIV with opportunistic infections, TB, gastroenteritis, malaria and stroke secondary to uncontrolled hypertension.

The hospital requested:

1. Help to interact with other DTCs from Mavalane or José Macamo, perhaps to be present in their meetings to have experience on how to start and how to work.

They will have a meeting this afternoon where they will talk about the need of DTC and start the process of identifying members for the committee. Neusa will send the TOR established by the MISAU on how the DTC should operate.

**Specific activities and intervention recommended for this Hospital:**
The hospital is new and no DTC exist. Start by creating a DTC with the assistance of MISAU and SIAPS:

**Structure and organization of the DTC**
- Obtain hospital management approval, including the director
- Develop multi-disciplinary membership from key stakeholders
- Collaborate with other organizations and committees in the hospital and community
- Develop action plans and objectives for the year
- Terms of Reference (TOR) (as provided by MISAU, Hospital Pharmacy) in place and approved
- Regular meetings, at least quarterly, with distribution of minutes

**Identification of medicine use problems**
- Discusses medicine use problems at regular meetings (and proposed solutions)
- Conducts medicine use studies when possible (WHO Health Facility Indicator studies, Medicine Use Evaluation (MUE))
- Conducts Prescription Norms Study regularly (studies of prescription format)
- Review of monthly medicines order to determine availability and appropriate quantities of medicines

**Implementation of Interventions to improvement medicine use**
- EML – monitors for compliance (revised EML)
- STG – ensures availability of all STGs approved by MISAU
  - Participates in STG compliance study for HIV/AIDS, malaria, hypertension
- Education - provides in-service education on important topics at the hospital - STGs, EML, medicine use problems, rational medicine use
- MUE – Conducts MUE (with evidenced-based criteria) on important, problem prone medicines
Pharmacovigilance

- Works with national Pharmacovigilance programs to implement a comprehensive programs at the DTC
- Supports Pharmacovigilance programs with the DTC including the reporting of adverse clinical events

Specific Recommended Activities

**Medicine use according to approved standards**

Comprehensive national guidelines are not available. There are guidelines for certain diseases (HIV-AIDS, TB, Malaria, STI, and hypertension) but no other national guidelines. The DTC will need do the following for treatment guidelines:

- Obtain all STGS available (those that have been approved by MISAU) including:
  - HIV-AIDS
  - Tuberculosis
  - Malaria
  - Hypertension
  - Sexual Transmitted Infections

- Ensure the guidelines are available in the appropriate sections of the hospital, ambulatory health facility and ER. These should be available in full form and as posters and wall charts. Practitioners throughout the hospital and health facilities must have immediate access to all approved guidelines.

- DTC provide training at hospital (in conjunction with national programs) on the use of STGs and where they are located in the health facility.

- Monitor the use of the guidelines by reviewing medical records periodically to determine compliance with the approved guideline, e.g., percentage of patients treated who are in compliance with approved STGs.

- Participate in the monitoring and use of guidelines - SIAPS/MISAU STG compliance MUE. This involves reviewing the medical records at the hospital, ambulatory clinic, and ER to determine if they follow the approved guidelines for HIV/AIDS, malaria, and hypertension. SIAPS will work directly with the DTC to conduct this MUE. See protocol in Annex E.

**Medicine Availability**

- Using the Mozambique EML and National Formulary determine if medicines are available from local warehouse. These documents will be made available by SIAPS.

- Ensure all prescribing is according to these approved lists.

- Work directly with local and national warehouse to ensure medicines are available, especially those for HIV-Aids, TB, and Malaria.
ANNEX H: MAPUTO CENTRAL HOSPITAL

Maputo Central Hospital

Present at the meeting:

Dr. Domingos Dias Diogo - Clinical Director of the hospital and chair of the DTC
Dr. Artur Luis - Deputy of the DTC
Dr. Hélio Gemo – Department of Hospital Pharmacy/MISAU
Dr. Aminofro Langa - Department of Hospital Pharmacy/MISAU
Dr. Neusa Bay – SIAPS MSH
Dr. Terry Green – International Consultant
Dr. Alda Mariano – National Consultant

Objective: to understand how the committee is working and progressing and how SIAPS and MISAU can provide assistance to improve their performance.

The hospital has approximately 1,500 beds. They have a DTC working and many other committees, for example: antibiotics, maternal, HIV/AIDS, oncology, and others. Dr. Diogo belongs to many committees and is the chair of several.

Dr. Diogo explained that a significant problem for the DTC and rational medicine use at this hospital is the poor availability of standards and the lack of compliance with those that exist. They have only the HIV/AIDS and hypertension STGs available because he was working within the national committee responsible to develop these STGs. These two STGs are available and staff has been trained on their use, but not enough copies are available in the hospital and clinics.

They have an internal STG on the use of antibiotics, particularly the use of 3rd generation cephalosporins, elaborated by the Antibiotics Committee. The use of this antibiotic is authorized exclusively by the clinical director, based on the evidence, diagnostic and sensitivity laboratory tests that should be attached to the request form filled by the prescriber.

Achievements of the DTC:

1. They discussed the structure of DTC, duties, TOR, etc.
2. They have a pharmacovigilance focal point at the DTC. MISAU has introduced pharmacovigilance to the committee and some activity has started.
3. They have legal authorization from MISAU to buy medicines for the hospital and they do not depend solely on Central Medical Stores. They have developed a list of medicines (local formulary) mainly with medicines to use at this hospital (4th Level). The Central Medical Store provides basic medicines like paracetamol, ibuprofen, and amoxicillin. Streptokinase has been problematic - they have months without the medicine and suddenly they receive a large distribution. Because of a low rotation for this medicine, they expire and they have to be destroyed (wasting a significant amount of money). The list (or formulary) was developed involving specialists from different areas and is considered to be a consensus list.
4. They developed another list for chronic conditions for example hypertension, diabetes, epilepsy and also medicines for psychiatric conditions. TB and AIDS medicines were excluded as well as oncology drugs.

5. They also have permission to use the money from a special clinic (where physicians attend private patients within the hospital). The money reverts to the hospital and this money is used to buy medicines for the intensive care unit like streptokinase (if it is not available from central medical stores) and other medicines for emergencies.

6. They are doing a study of the bacteriology and antibiotic sensitivities in the hospital and have found the main organism identified is staphylococcus aureus.

7. The hospital is working to develop a protocol to treat cardiac failure.

Maputo Central Hospital staff asked SIPAS and MISAU for the following:

- Take part in their meetings and develop minutes to help them to improve the performance of the DTC. In the next meeting they will draw up a work plan for the next six months.
- Provide a tool to evaluate the use of antibiotics in the hospital
- Extend the use of STGs and to supply enough copies of the STGs to each of the Departments of the Central Hospital of Maputo and provide training on how to use the guidelines.

Recommended hospital and SIAPS activities:

- Work with this hospital as requested by attending meetings and help to produce agenda and minutes.
- Obtain all approved STGs and distribute to hospital to make readily available in hospital units, ER, and OPD clinics.
- Train staff on use of STGs (this will be done by DTC in the hospital)
- Participate in the STG compliance MUE (HIV/AIDS, Malaria, hypertension). See protocol in Annex E. SIAPS will work directly with the hospital to conduct this MUE
- Conduct a study of antibiotic use in the hospital using the SIAPS manual: How to Investigate Antimicrobial Use in Hospitals: Selected Indicators. Some of these indicators include:
  a. Existence of standard treatment guidelines (STGs) for infectious diseases
  b. Existence of an approved hospital formulary list or essential medicines list (EML)
  c. Availability of a set of key antimicrobials in the hospital stores on the day of the study
d. Average number of days that a set of key antimicrobials is out of stock

e. Percentage of hospitalizations with one or more antimicrobials prescribed

f. Average number of antimicrobials prescribed per hospitalization in which antimicrobials were prescribed

g. Percentage of antimicrobials prescribed consistent with the hospital formulary list

h. Average duration of prescribed antimicrobial treatment

i. Percentage of patients who receive surgical antimicrobial prophylaxis for cesarean section in accordance with hospital guideline

j. Average number of doses of surgical antimicrobial prophylaxis prescribed for cesarean section procedures

k. Percentage of antimicrobials prescribed by generic name

l. Average duration of hospital stay of patients who receive antimicrobials

SIAPS will assist in conducting this study with a special emphasis on indicators I and J, cesarean section antibiotic prophylaxis. From this study, SIAPS can then work with this hospital to develop a protocol for cesarean section antibiotic prophylaxis using a single dose of a first generation cephalosporin, 1 hour before surgery. This protocol and subsequent compliance will lead to rationalizing antibiotic use in the hospital for surgical antibiotic prophylaxis.
ANNEX I. POWERPOINT SLIDES FOR WORKSHOP

**Medicine Use Overview**

Objectives

- Define appropriate use of medicines.
- Understand the problems of inappropriate use
- Illustrate factors contributing to inappropriate medicine use.
- Explain the consequences of inappropriate medicine use on individual patient outcomes, public health, and the healthcare system.

Outline

- Defining appropriate medicine use
- Problems and determinants of inappropriate use
- Consequences of inappropriate use
- Process for addressing problems in medicine use

**What is Medicine Use?**

Medicine use is the result of actions or decisions occurring during the interactions of health care providers (medicine prescribers, dispensers, and sellers) and end users of the medicine (patients, consumers).

These behaviors or practices relate to the process of diagnosing the condition, prescribing medicines, filling, packaging and dispensing the product, and taking the medicines as instructed. (MDS-5 Chapter 27)

**Improving Use of Products and Services**

What is Use Appropriate?

- The rational use of drugs requires that the patient receive medicines appropriate to their clinical needs, in doses that meet their individual requirements, for an adequate period of time, and at the lowest cost to them and their community.

    "WHO, Guidelines on Essential Use of Drugs, 2000"

Health Facilitiyes | Laboratories | Pharmacies | Drug Shops | Community | Housesholds

- Systems
- Providers
- Dispensers
- Technicians
- End Users
- Patients
- Caregivers

Medicine use accounts occur in many environments: public and private settings, at health care facilities, laboratories, private pharmacies or drug shops, as well as at the level of the household.
Annex I

Problems of Inappropriate Use –

Inappropriate use includes:
- Use of drugs when no drug therapy is needed
- Incorrect medicine for a particular indication
- Use of medicines of uncertain or unknown efficacy
- Use of medicines of uncertain safety
- Failure to prescribe available, safe and effective medicines
- Incorrect dosage or regimen

Problems of Inappropriate Use - Prescribing Practices

Prescribers
- Overuse of antibiotics
  - Use antibiotics for viral or other conditions not needing an antibiotic
  - Use of antibiotics for a particular condition
  - Use of antibiotics in a particular situation
- Overuse of injections when other dosage forms work as well or better
- Polypharmacy – multiple prescriptions
- Overuse of vitamins and “tonics”
- Undue use of essential medicines, i.e., antihypertensives
- Prescribing for every patient symptom
- Prescribing highly promoted medicines with questionable efficacy

Problems of Inappropriate Use - Dispensers

- Incorrect interpretation of prescriptions
- Dispensing the wrong medication
- Inadequate labeling
- Inadequate counseling

Problems of Inappropriate Use - Patients

- Did not obtain (or take) medicines
- Sharing medicines with others
- Poor adherence to prescribed medicines

Determinants of Inappropriate Use - Health Systems

- Medicine supply
  - Inefficient management (example: pre-narcotic and distribution are not effective in reducing medicine stock)
  - Non-availability of required medicines (example: lack of funds, pharmacy, health facilities, using free, community-owned medicines)
- Inappropriate medicines
  - Insufficient education and training programs on proper medication use

Determinants of Inappropriate Use - Prescribers

Internal factors
- Lack of education (example: too many patients, too many appointments)
- Lack of experience (example: too many appointments)
- Lack of knowledge (example: too many appointments)
- Pressure from patients to prescribe (example: patients believe they need medication for every symptom)

External factors
- Want patients to prescribe (example: patients believe they need medication for every symptom)
- Presence of health professionals (example: too many appointments)
- Pressure from patients to prescribe (example: patients believe they need medication for every symptom)

Determinants of Inappropriate Use - Dispensers

Internal factors
- Lack of knowledge (example: too many appointments)
- Lack of experience (example: too many appointments)
- Pressure from patients to prescribe (example: patients believe they need medication for every symptom)

External factors
- Lack of supervision (example: too many appointments)
- Lack of experience (example: too many appointments)
- Pressure from patients to prescribe (example: patients believe they need medication for every symptom)
Determinants of Inappropriate Use - Patients and Community

- Cultural beliefs
- Communication skills
- Unable to understand directions and counseling provided
- Limited time available for counseling (example: waiting times for consultations and to obtain medicines are long and mean little time for counseling)
- Inaccurate user information (example: untrustworthy information leaves reality available and consequently optimal treatment is not provided).

Determinants of Inappropriate Use - Industry

- Community beliefs about the efficacy of certain medicines and methods of administration (example: community has the belief that traditional treatment of many diseases can be done with local herbal remedies that a single Western medicine is based on knowledge and is believed that treatment is effective even when it is not necessary)
- Financial gain (example: some financial gain are the result of providing many similar medicines but to have inefficacy; unsafe and low quality products. Financial gain can lead to significant inappropriate use)
- Misleading salesmanship (example: spread across different points within articles provide that provide misleading information to support their products)

Consequences of Inappropriate Use –

- Increased Mortality and Morbidity
- Increased Adverse Medicine

- Example: 
  - Oral rehydration solution is proven to be effective and safer to treat simple diarrhea in children – unnecessary exposure to unsafe use of needles for unnecessary exposure to infections

- Example: 
  - An overdose of gentamicin can lead to permanent hearing loss.
  - Prescribing antibiotics for viral conditions leads to an increase in the number of allergies reactions.

Consequences of Inappropriate Use – Antimicrobial Resistance

- Infections diseases kill 12-15 million people annually, 95% of whom live in resource-constrained countries
- The major life-saving intervention for infectious diseases is antimicrobial treatment.
- But when antimicrobial medicines are used unnecessarily, or in doses that are inadequate, these pathogens develop resistance to these medicines and the spread of treating infections.

Consequences of Inappropriate Use – Psychosocial

- Psychosocial –
  - Unnecessary prescribing encourages patients to believe that they need medications for any and all conditions, even trivial ones
  - Previous overuse of injections led physicians to consider them the best treatment, when in fact they are rarely needed.
  - Studies have shown that increased patient expectations of the benefit of medicines, and the increased demand for prescriptions tend to lead prescribers to provide unnecessary antibiotics for viral infections.
Annex I

What Do We Mean by Improving Use?

Improving use requires a change in actions and behavior of health systems, health professionals, and patients to ensure the safe, appropriate use of medicines. There is a need to understand:

- Nature of medicine use including social, cultural and economic context
- A standardized approach to measuring medicine use problems
- Efficient and effective use of interventions and strategies to address the medicine use problem

How Do We Go About Addressing the Problems of Medicine Use?

- Improving use requires a change in behaviors and practices of all actors involved in the process of medicine use.
- MNH and the International Network for the Rational Use of Drugs proposed a process for changing medicine use behavior. This process follows a pathway similar to the way physicians make a diagnosis and decide on treatment (which explains the terms used):
  - Examine – the current situation is observed and measurements of the problems in medicine use are conducted
  - Diagnose – the underlying reasons determining an influencing the problem behavior are thoroughly investigated by a variety of qualitative and quantitative methods

How Do We Go About Addressing the Problems of Medicine Use? (2)

- Treat: Interventions to address the future or underlying causes of the inappropriate practice or behavior that have been proven to modify the problem behavior or practice are proposed. After analyzing that resources are available and the interventions are feasible, they are implemented usually in pilot sites.
- Follow-up: Intended and unintended changes in behavior are monitored throughout the period of intervention. Intervention may be modified if needed. Outcomes are measured, and decisions are made on whether the initial diagnosis of the cause of the problem was correct.

An Overview of the Process of Improving Medicine Use

1. EXAMINE Measure Practices (Descriptive Quantitative Studies)
2. FOLLOW UP Assess Changes in Outcomes (Quantitative and Qualitative)
3. TREAT Design and Implement Interventions (Collect Data to Measure Outcomes)
4. DIAGNOSE Identify Problems and Causes (In-depth Qualitative and Quantitative Studies)

The DTC and Appropriate Medicine Use

- Medicine use problems are complex, widespread, costly, and affect quality of care at all levels of the health system
- Identifying the problems, understanding why they occur, and implementing interventions to improve or resolve requires a multifaceted approach by a highly skilled team of professionals
- The DTC provides the organization, skilled professionals, and the mandate to address the many problems of medicine use and ensure use is rational

Summary

- Appropriate medicine use is essential to ensuring good patient health outcomes
- Inappropriate use contributes to increased morbidity/mortality, development of antimicrobial resistance, and substantial increases in health care costs
- Improving a medicine use problem or practice requires a methodology that will identify what the problem is and why it exists and a standardized approach to change the practice or behavior.
Objectives

- Understand basic concepts of conducting a Medicine Use Evaluation
- Describe the steps to implement a MUE
- Describe the case study using MUE in surgical prophylaxis
- Understand how MUE can be used in Mozambique to address a medicine use problem

Outline

- Introduction and objectives of a MUE
- Stepwise Approach to Implementing a MUE
- Case Study Using an MUE in surgical prophylaxis medicine use problem
- Summary

Medicine Use Evaluation (MUE) - Introduction

- Ongoing, systematic, criteria-based program of medicine evaluations that will ensure appropriate medicine use. Interventions are necessary when inappropriate therapy is identified.
- A MUE will—
  - Define appropriate medicine use (by establishing criteria)
  - Audit criteria against what is being prescribed
  - Give feedback to prescribers on all identified problems
  - Monitor to see if criteria are followed and prescribing is improved

Objectives of a MUE

- Ensure that pharmaceutical therapy meets current standards
- Promote optimal medication therapy
- Prevent medication-related problems
- Identify areas in which further evaluation is needed
- Create criteria for appropriate medicine use
- Define thresholds for quality of medicine use below which corrective action will be undertaken
- Enhance accountability in medicine use
- Control pharmaceutical costs

Stepwise Approach to MUE

1. Establish responsibility.
2. Develop scope of activities.
3. Establish criteria.
4. Define and establish thresholds.
5. Collect data and organize results.
6. Analyze data.
7. Develop recommendations and plan of action.
8. Conduct MUE follow-up.
Step 1. Establish Responsibility
- Drug and Therapeutics Committee (DTC) is logical choice
  - Multidisciplinary committee dealing with all facets of medicine therapy—has the necessary expertise
  - Subcommittee of the DTC
    - Must include representation of practitioners whose medicine prescribing will be assessed

Step 2. Develop Scope of Activities
- Identify medicine therapy problems to be addressed
  - Using ABC/VEN analysis, ADR reports, AMR reports
  - Concentrate on medicines with highest potential for problems
  - High volume
  - Low therapeutic index
  - HighADR rate
  - Expensive medicines
  - Critically important medicines
  - Antiinfective
  - Injectables
  - Medicines undergoing evaluation for addition to the formulary
  - Medicines used for off-label indications
  - Medicines used for high-risk patients

Step 3. Establish Criteria
Criteria to define correct medicine use (using evidence-based medicine)—
- Appropriate medicine for medical condition
- Correct dose and quantity dispensed
- Preparation for administration
- Monitoring is appropriate (e.g., laboratory test)
- Communications
- Medication Interactions
- Medicine administration (especially for injections)
- Patient education (written and oral instructions)
- Patient outcomes (e.g., blood glucose, glycosylated hemoglobin)
- Pharmacy administrative indicators (correct cost, billing)

Step 4. Define and Establish Thresholds
- Define and establish thresholds or benchmarks for quality of medicine use below which corrective action will be undertaken
- Thresholds define the expectations or goals for complying with the criteria (e.g., 40% of prescriptions for 3rd generation cephalosporins are for pediatric serious infections)

Step 5. Collect Data and Organize Results
- Prospective evaluation
  - Done as medicine is prepared or dispensed to the patient
  - Pharmacist can intervene at the time the medicine is dispensed
- Retrospective evaluation
  - Requires access to medical records
- Data sources
  - Patient charts, medical records, prescriptions, laboratory files
  - Manual systems versus computerized systems
  - Needs minimum of 50–75 records

Step 6. Analyze data
- Tabulate results for each indicator
- Analyze to see what percentage of prescribing episodes comply with the criteria and whether the threshold is met, for example, 70% of patients prescribed 3rd generation cephalosporins were given it for predefined criteria—20% short of threshold
- Determine why thresholds (benchmarks) are not met
- Analyze data quarterly or more frequently
**Step 7. Develop Recommendations and Plan of Action**

- Recommendations to address—
  - Inappropriate medicine use
  - Unacceptable patient outcomes
  - Interventions to resolve any medicine use problems
- Methods to resolve medicine use problems
  - Education
  - Medicine order forms
  - Prescribing restrictions
  - Formulary manual changes
  - STG changes

**Step 8. Conduct MUE Follow-up**

- Check to see that recommendations have been implemented.
- Re-evaluate MUE to see if problems with pharmaceutical therapy have been resolved.

**MUE Case Study—Antibiotic Prophylaxis in Cesarean Section, Jordan**

**Study setting:**
- A retrospective study was conducted over 1 month in 4 hospitals in Jordan.
- Antimicrobial surgical prophylaxis for C-section was shown to use multiple antibiotics in multiple doses over extended periods of time. Predominant use of high once 2nd and 3rd generation cephalosporin antibiotics. First dose administration was inserted in most patients (after the surgical procedure)

**Interventions:**
- C-section antimicrobial prophylaxis protocol was developed to include a single dose of a single antibiotic within 1 hour of surgery, e.g., ceftaxin.
- Education provided to physicians and protocol approved by the DTC

**Measuring the Existing Situation, Baseline Analysis**

Example of a C-section antibiotic prophylaxis regimen at 1 hospital

- **Pre-op and surgery**
  - No antibiotic
  - No prophylaxis

- **Antibiotic section**
  - Amoxicillin 1 gm every 6 Hours 3 doses OR
  - Cefuroxime 750 mg every 6 hours x 2 days (Loading dose)
  - Metronidazole 500 mg every 8 hours x 3 doses (THOR
  - Cefixime 500 mg 4 times a day for 5 days

- **At discharge**
  - Cefixime 500 mg 4 times a day
  - Tazobactam 500 mg 3 times a day

**Summary of prophylactic antibiotic administration C-section at 1 hospital**

- **Pre-op**
  - 1 gm of amoxicillin
- **Intra-op**
  - 1 gm of amoxicillin
- **Post-op**
  - 2 gm of amoxicillin
- **Discharge**
  - 1 gm of amoxicillin

**Establish Criteria (Guideline)**

Initially developed evidence-based recommendations on antibiotic prophylaxis for C-section. A comprehensive search of the literature provided single evidence from systematic reviews (RCT and other high-level evidence) that a single antibiotic given in a single dose within one hour before the surgical procedure was sufficient for prophylaxis. Available local studies or references were also included.

Baseline profiling done prior to the workshop had shown that the local practices at the participating hospitals did not match with the current best international evidence and recommendations in terms of the choice of antibiotic and dosage, timing of administration, and duration of prophylaxis.
Establish Criteria (Guidelines) for Antibiotic Prophylaxis and Interventions

Based on initial assessment of current practices, stakeholder interviews, and surgical prophylaxis evidenced-based review, the interventions and intervention profile as follows:

- Development of clinical practice guidelines or protocols to enhance effective, safe, and cost-effective use of medicines. A participatory, transparent, and evidence-based development process will be used that engages key stakeholders in this development.
- Documentation of specific policies and procedures at the hospital and national level to incorporate the protocols and make them a policy.
- Education and training at the hospital level on key concept of evidenced-based antibiotic prophylaxis for common surgical and CCI concepts to implement the protocols.

Establish Criteria (Guidelines) for Antibiotic Prophylaxis

- All four hospitals were able to complete the protocol developed.
- Although each hospital drafted its own PPP individually without the participation of other hospitals, the resulting hospital-specific protocols and procedures were in fact very similar. When armed with the latest international medical evidence, the teams from each hospital opted to adhere to the evidence, and the resulting protocols therefore contained many similarities.

MUE follow-up and Outcome Measures (analyze data)

- The key indicators agreed for longitudinal tracking included:
  - Adherence to protocol recommended antibiotic
  - Time of administration of first dose of prophylactic antibiotic
  - Administration of the appropriate number of antibiotic doses
  - Rates of surgical site infection
  - Cost savings (as compared to baseline studies of cost)

MUE follow-up and Outcome Measures (2)

- The attached table combined results for 2012 for all the key program elements at all three hospitals. These results indicate good compliance to the protocols and procedures in terms of the use of the antibiotic of choice (certain), use of a single dose (except in cases with pre-identified exceptions), and administration of the antibiotic prior to skin incision (within an hour before skin incision).
- The use of the new protocols also resulted in substantial cost savings when compared with the cost of antibiotics used during the baseline period. All these results were achieved with a low overall surgical site infection rate of 1.50%.
Extrapolated Total Annual Cost-saving for all CS Cases

Conclusions of Jordan MUE

- The study showed that irrational antimicrobial use in the surgical prophylaxis field is excessive
- The common problems regarding use of antimicrobials in surgery were:
  - Inappropriate choice of antimicrobial
  - Inappropriate duration
  - Using the new generation of antibiotics which are costly
  - Inappropriate administration times
- The MUE was instrumental in improving use of surgical antibiotics and lower overall cost of medicine treatment

Summary

- MUE is an audit and feedback intervention where medicine use can be reviewed against approved criteria
- Requires establishing criteria and thresholds and then reviewing medicine use to determine if therapy is appropriate
- Feedback to prescribers is necessary to improve prescribing (educational, managerial, regulatory interventions may be required)
 Annex I

**Mozambique Essential Medicines List (EML)**

**Objectives**
- Understand the WHO essential medicines concept
- Describe the benefits of an essential medicine list and concept
- Describe the process of revising a national essential medicine list
- Understand how to manage an EML at the health facility level

**Outline**
- Complexities of medicine use
- Essential medicines concept and situation in Mozambique
- National Essential Medicine List revision process
- Managing the EML at the health facility: key DTC activity
- Summary

**Drug and Therapeutics Committees - functions and activities**

**Complexities of Medicine Use**
- Hundreds of thousands of medicine are available worldwide
- Several therapeutic groups and medicines are available to treat any specific disease
- New medicines and new information about existing medicines are emerging

**Complexities of Medicine Use (2)**
- Developing countries spend up to 40% of their health care budgets on medicines on medicines
- An estimated 70% of medicines are considered duplicative or non-essential
- Lack of access to medicines is a major and chronic issue in resource-constrained settings
- Lack of availability erodes public confidence in the public health system
- In low and middle-income countries, most people pay for their own medicines
Situation in Mozambique

- MISAU has made great strides to improve healthcare to the people of Mozambique
- Challenges remain—only 40-50% of the population have regular access to public health services and more than 70% of the population used traditional medicines primarily to treat health-related problems
- The lack ofắng makes RMU in the country
- The lack of a updated EML contributes to many medicine use problems and provides the opportunity to prescribe unnecessary and irrational medicines.
- Mozambique EML is under revision this year

Essential Medicines Concept

- Careful selection and implementation of a limited list of essential medicines enhances access and rational use of medicines
- Global and national policy makers and health program managers support the concept of essential medicines
- The essential medicines concept is a key element of national medicines policies
- WHO has promoted this concept for 35 years and regularly publishes a Model List. This important publication was updated in April 2013 and can be used to revise a national EML

Summary of Benefits of an Effective EML

- SUPPLY
  - Easier procurement
  - Lower amount of stocks
  - Improved quality assurance
  - Easier dispensing
- PATIENT USE
  - Focused education efforts
  - Better compliance
  - Improved availability
- PRESCRIBING
  - Promotes RMU
  - More experience with fewer medicines
  - Rational alternatives not possible
  - Focused medicine information
  - More easier to manage
- COST
  - Lower prices, more competition

National Essential Medicines List - Mozambique

- The National Essential Medicines List (NEML) is a vital part of MISAU strategy to provide comprehensive high quality health care in Mozambique
- A revision process has started and a new NEML committee formalized and selected

Key steps to produce a revised NEML in Mozambique

- 1. Identify stakeholders involved in medicine use
- 2. Conduct needs assessment
- 3. Develop a list of necessary medicines
- 4. Review and revise the list
- 5. Implement the revised list
- 6. Monitor and evaluate the process
Annex I

Managing the EML at the Health Facility – Key DTC activities

- Ensure NEML is available in the health facility
- Monitor prescribing and use of medicines for compliance with the NEML
- Outcome measures - % of prescriptions in accordance with the EML
- Provide education and training for health care professionals at the health facility concerning use of the NEML
- Request medicines for addition to the NEML if necessary, using standardized applications and transmit to the national EML committee

Summary

- The essential medicines concept has become an established approach in international public health and is supported by most governments of the world
- The EML provides extraordinary benefits for rationalizing medicine prescribing and use, easier and less costly procurement, enhanced inventory management and improved use and acceptance by patients.
- MISAU endorses the essential medicines concept and is in the process of revising the national essential medicines list
Interventions and Strategies to Improve Medicine Use, Standard Treatment Guidelines

Objectives

- Understand the how treatment guidelines are developed
- Describe the use of treatment guidelines in Mozambique
- Explain how treatment guidelines can be used to improve medicine use

Outline

- Irrational use of medicines
- Strategies to improve Medicine Use in Developing and Transitional Countries
- Introduction to Treatment Guidelines
- Guidelines available in Mozambique
- Case studies - treatment guideline and improving medicine use
- Summary

Irrational Use of Medicines

Globally, more than 50% of medicines are prescribed, dispensed, or sold inappropriately

Consequences of Irrational Medicine Use

- Increased mortality
- Increased morbidity
- Increased adverse drug events
- Increased drug resistance
- Increased cost and wasted resources
- Financial hardships

Irrational Treatment of ARI in Developing and Transitional Countries

Irrational Prescribing of Antibiotics in Developing and Transitional Countries
Strategies to Improve Medicine Use in Developing and Transitional Countries

Interventions to Improve Medicine Use
- Effective interventions to improve use of medicines are generally multi-faceted
  - Provider and consumer education with supervision
  - Peer review and self monitoring (MUE)
  - Community case management
  - Essential Medicines Program
- Printed materials alone have little effect
- The use of guidelines to be effective need to be accompanied by reminders, educational outreach and feedback

Standard Treatment Guidelines—Introduction
- Treatment of diseases may have many different approaches
- Many practitioners will not remember the best method of treatment
- Applying the most effective treatment benefits both the patient and the health care system
- Formulary management will have only limited impact if the medicines are used incorrectly

Treatment Guidelines—Advantages for Health Care Providers and Patients
- Provides standardized guidance to practitioners
- Promotes high quality of care by directing practitioners to the most appropriate medicines for specific conditions
- Utilizes only essential or essential medicines, so the health care system need to provide only medicines in the STGs
- Provides assistance to all prescribers, especially to those with lower skill levels
- Enables providers to concentrate on making the correct diagnosis
- Patients receive optimal pharmaceutical therapy
- Enables consistent and predictable treatment from all levels of providers and at all locations
- Allows for improved availability of medicines because of consistent and known usage patterns
- Helps provide good outcomes because patients are receiving the best treatment regimen available
- Lower cost

Advantages to Healthcare Officials and Supply Management
- Healthcare Officials
  - Enables a cost for ensuring quality of care provided by health care professionals
  - Enables effective therapy in terms of quality
  - Enables a system for controlling costs
  - Enables information for practitioners to give to patients concerning the medicines a patient can receive
  - Serves to integrate national programs into health services. In the primary health care center with a single set of guidelines
- Supply Management
  - Utilizes only formularies or essential medicines, so the health care system needs to provide only medicines in the STGs
  - Provides information for forecasting and ordering
  - Provides information for purchase of prepackaged medicines

Disadvantages
- Inaccurate guidelines will provide the wrong information. Often guidelines are based on existing practices rather than evidenced-based medicine.
- Guideline development and maintenance takes much time and effort.
- STGs may give false sense of security and discourage ongoing critical thinking.
Establishing the Guideline

- Important considerations:
  - Create from evidence-based sources
  - Choose cost-effective treatments
  - Use medicines from the national EML
  - Involve respected clinicians and specialists

What Various Studies Are Used to Evaluate?

- Meta-analysis: Usually for treatment efficacy and safety
- Randomized controlled trials: Usually for treatment efficacy or diagnosis
- Cohort study: Usually for prognosis, harm, etiology, prevention
- Case-control study: Usually for prognosis, harm, etiology, prevention
- Case series: Usually for harm

Not all Evidence is Equal - Levels of Evidence

<table>
<thead>
<tr>
<th>Recommendation Grade</th>
<th>Level of Evidence</th>
<th>Study Characteristics in Decision Making</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Lower</td>
<td>Systematic review (SR) with heterogeneity; SR ICs</td>
</tr>
<tr>
<td>B</td>
<td>Lower</td>
<td>Individual RCT with narrow confidence interval</td>
</tr>
<tr>
<td>C</td>
<td>Higher</td>
<td>All or none study</td>
</tr>
<tr>
<td>D</td>
<td>Highest</td>
<td>SR with homogeneity of patient studies</td>
</tr>
<tr>
<td>E</td>
<td>Highest</td>
<td>Individual cohort studies (excluding for quality RCT)</td>
</tr>
<tr>
<td>F</td>
<td>Highest</td>
<td>Outcomes research, ecological studies</td>
</tr>
<tr>
<td>G</td>
<td>Highest</td>
<td>Systematic review, meta-analysis of case-controlled studies</td>
</tr>
<tr>
<td>H</td>
<td>Highest</td>
<td>Individual case-controlled studies</td>
</tr>
<tr>
<td>I</td>
<td>Highest</td>
<td>Case series (and poor quality cohort and case-controlled studies)</td>
</tr>
<tr>
<td>J</td>
<td>Highest</td>
<td>Expert opinion without explicit criteria</td>
</tr>
</tbody>
</table>

Guidelines Available in Mozambique

- Official MOH Guidelines:
  - HIV, ?
  - TB, ?
  - Malaria, ?
  - Diabetes, 2000
  - Malaria, 2011
  - Mental Health, 2005
  - Hypertension, 2011

Guidelines Available in Mozambique

- Unofficial Guidelines
  - Pediatric medical conditions - several different guidelines and protocols, 2009-2012
  - Others:

Case Study - Use of Standard Treatment guidelines, Namibia

MOH in partnership with SIAPS, conducted an assessment of compliance of prescribers with the Namibia Standard Treatment guidelines. The main objective of the assessment was to compare prescribing practices before and after the roll out of SFUs that were initially disseminated in 2011.

The assessment also aimed to explore factors associated with compliance and to find out what activities were implemented in health facilities and regions to promote compliance with the SFUs.
Case Study - Use of Standard Treatment guidelines, Namibia

- The assessment covered 13 health facilities, including six hospitals, four health centers, and 3 clinics.

- A total of 1,090 prescriptions were reviewed concerning eleven diseases: Asthma, URI, community acquired pneumonia, diarrhea without blood, diabetes mellitus type 2, hypertension, intestinal helminthiasis, HIV/AIDS.

Case Study - Use of Standard Treatment guidelines, Namibia

- Compliance of prescriptions with the STGs was assessed using strict and loose criteria.

  - Strict Criteria – requires that prescriptions to fully comply with the stipulations of the STG

  - Loose criteria – allowed for some deviation in the dose and duration of treatment, non-use of generic name, and use of additional medicines, such as analgesics and multivitamins

Case Study - Use of Standard Treatment guidelines, Namibia

**Results:**

- The findings show that overall compliance with STGs using strict criteria was 26.2%. Compliance using the loose criteria was 55.1%

- Using strict criteria, the highest disease state with compliance was HIV/AIDS at 63.5%

Case Study - Use of Standard Treatment guidelines, Namibia

**Reasons for poor compliance (from interviews and questionnaires):**

- Lack of personal STG copies for the prescribers
- Lack of time to read the guidelines
- Lack of adequate copies for the health facilities
- Poor attitude of health workers about STGs
- High patient workload

Case Study - Use of Standard Treatment guidelines, Namibia

**Results using Strict Criteria:**

- HIV/AIDS: 63.5%
- Urinary Tract Infection: 49.5%
- Diabetes (type 2): 40.2%
- Intestinal Helminthiasis: 30.6%
- Oral Candidiasis: 27.9%
- Vaginal Discharge: 26.1%
- Asthma: 22.3%
- Pneumonia: 19.4%
- Hypertension: 14.5%
- Viral URI: 1.6%
- Diarrhea without blood: 0%

**Results using Loose Criteria:**

- HIV/AIDS: 79.8%
- Urinary Tract Infection: 86.1%
- Diabetes: 74.1
- Intestinal Helminthiasis: 62.1%
- Oral Candidiasis: 54.9%
- Vaginal Discharge: 93.0%
- Asthma: 60.0%
- Pneumonia: 42.4%
- Hypertension: 56.1%
- Viral URI: 33.4%
- Diarrhea without blood: 15.6%

Source: Namibia SIAPS program, Chongo, L., Gwaze, G., Mafahamure, M., Muzvekwa, M., and Muzvekwa, M.
Case Study 2 – Treatment Guidelines for HIV in South Africa - poor compliance in switching to second line medicines

- The scaling up of ART in South Africa has resulted in a dramatic increase in the number of patients receiving ART. The length of ART treatment may lead to increased risk of side effects and treatment failures. The cost of this second line therapy is significantly higher than first line treatments.

- In South Africa, SIAPS collaborated with national stakeholders to help conduct a medicine use study in Gauteng Province, which identified that 50 percent of patients receiving antiretroviral therapy, the switch from first-line to second-line regimens was not in compliance with treatment guidelines.

Conclusions

- Evidenced-based treatment guidelines will help ensure national medicine use.

- The first step is to have the approved national guidelines readily available in the health facility.

- Guidelines must be used with appropriate provider education and monitoring/provider feedback in order to be effective.

- Monitor the use of important guidelines and determine compliance and outcomes.
Annex I

Objectives

- Understand why a DTC is important in Mozambique
- Describe the major functions and activities of a DTC to improve medicine management and use
- Describe how a DTC performance is monitored and impact measured
- Understand the DTC implementation process

Outline

- Why DTCs are important
- Activities and functions of the DTC
- Monitoring DTC and intervention performance
- Implementing the DTC – Getting Started
- Summary

Why DTCs are Important
Globally, more than 50% of medicines are prescribed, dispensed, or sold inappropriately

Consequences of Irrational Medicine Use

Increased mortality
Increased morbidity
Increased adverse drug events
Increased drug resistance
Increased cost and wasted resources
Financial hardship

Why DTCs are Important – Adverse Clinical Events occur frequently and must be managed and prevented

- Medication Errors
- Adverse Drug Reactions
- ADVERSE CLINICAL EVENTS
- Poor Quality Medicines
- Counterfeit Medicines
**Why DTCs are Important - The Global Threat of Antimicrobial Resistance**

AMR is:
- A steadily increasing global public health threat
- Widespread in both the hospital and community
- Rapidly making many 1st line treatments ineffective
- Impacting all infectious diseases, including HIV/AIDS, TB and malaria

![AMR Diagram](image)

**How do DTCs Improve Medicine Use?**

- **DTC** is the cornerstone for managing the medicine use process
  - Uses skilled local health professionals at hospitals and clinics to review, monitor and manage medicine use
  - Ensures medicines prescribed are according to established standards
  - Ensures medicines are safe, effective and are of high quality and are cost-effective

![DTC Use Diagram](image)

**Key Activities and Functions of the DTC - Interventions to Improve Medicine Use**

- Educational programs:
  - Educational bulletins and newsletters
  - In-service education
  - Face to face education (in-service, workshop)
- Managerial programs:
  - Adoption and use of rational standard treatment guidelines (use of national level DTCs and limited development of local protocols)
  - MUE
- Regulatory programs:
  - Pharmaceutical registration
  - Professional licensing
  - Licensing of entities

![DTC Education Diagram](image)

**Key Activities and Functions of the DTC - Managing Adverse Clinical Events**

- DTC needs to monitor and report Adverse Clinical Events including:
  - Adverse Drug reactions
  - Medication errors
  - Poor quality medicines
  - Counterfeit medicines
- Work directly with national Pharmacovigilance Program

![DTC Reporting Diagram](image)
Annex I

Matching Intervention Strategies With Problem Behavior

Educational
- to persuade —
  - formal and informal
  - reliance on materials

Managerial
- to guide —
  - target providers, systems
  - improved drug selection

Economic
- to induce —
  - provider: budgets, incentives
  - patient: shared costs

Regulatory
- to restrict —
  - barriers to market
  - enforcement

Monitoring DTC Performance: Process Indicators

- Have DTCs or hospital formulary been developed, adopted, and implemented?
- How many education programs were presented in the last year?
- How many intervention studies to improve medicine use have been conducted?
- Is there any documented policy for controlling access of pharmaceutical representatives and promotional materials in hospitals?

Monitoring DTC Performance — Impact and Outcome Indicators

- Medicine selection
  - number of medicines in the hospital
  - % prescribed drugs belonging to the hospital EMU

- Prescribing quality
  - % of prescriptions with and antibiotic prescribed
  - % of patients treated in accordance with guidelines
  - % of pharmaceutical treatments meeting agreed criteria of MUC

- Patient care
  - % of patients with adequate knowledge of medicine dosage

- Drug safety
  - Number Adverse Medicine Events documented and reported

DTCs—Guiding Principles

- Transparent and unbiased decision making
  - Explicit criteria and process
  - Documentation
  - Absence of conflict of interest including pharmaceutical manufacturers and suppliers
  - Development and enforcement of a strict ethics policy for all activities of the committee

- Objectivity — Evidence-based approach and levels of evidence

- Consistency — Uniformity between formulary and STOs and between regional and national health care programs

- Impact orientation — Indicators of process, impact, and outcome

Summary - Drug and Therapeutics Committees at the Health Facility Level

Identification of Medicine Use Interventions

Hospital DTCs

Training/Edcs

Medicine Use Interventions

Collaborations with hospital departments

Manage essential medicines lists

Monitor and implement

Monitor compliance

Implementing the DTC - Getting Started

- First Steps
  - Get approval and buy-in from Ministry of Health, hospital administration, and senior physicians
  - Develop terms of reference (TOR) — available from MOH
  - Develop Policies and procedures
  - Develop Objectives for the committee

- Select members
  - Representing key stakeholders from hospital administration, medical, pharmacy, and nursing
Implementing the DTC DTC — Structure and Organization, example

- Plan for regular meetings and regular attendance with documented and circulated agenda and minutes
- Documented goals, terms of reference, pollides, AND ALL decisions of the committee

Implementing the DTC — DTC Structure and Organization

- Plan for regular meetings and regular attendance with documented and circulated agenda and minutes
- Documented goals, terms of reference, pollides, AND ALL decisions of the committee

Implementing the DTC

- The way to get started will depend on local circumstances, including the health care system and hospital
- DTCs have to deal with many issues but cannot do everything all at once — so concentrate on only 1-2 issues at a time especially in the beginning
- The first step is for YOU to realize there is a problem and that the DTC can provide a framework for solutions
- Thereafter, you must convince others of the need to address the problem and work with them on solutions

Implementing the DTC

- Build evidence for advocacy by determining —
  - Whether data on medicine use problems is available. If so, collect it.
  - Whether senior health staff think medicine use problems exist. If so —
    - What kind of problems?
    - How serious are they?
    - How can the most serious problems be addressed?
    - Document what they say

Implementing the DTC

- Measure Your Medicine Use Problem
  - Involve senior staff in these important activities —
    - VEN analysis
    - ABC analysis
    - Medicine use indicator studies (health facility and hospital indicators)
    - Qualitative studies to determine why a problem occurs

Implementing the DTC

- Present Findings, and Plan the Next Steps with your Stakeholders
  - Analyse potential medicines use problems and obtain consensus on how to solve them
  - If causes are well understood, then solutions can be found by stakeholders. If causes are unknown, then qualitative studies should be conducted to determine why a medicine use problems occurs
  - Discuss and agree with stakeholders and senior prescribers a plan of action which may include —
    - Targeted intervention based on the derived findings and involving the senior prescribers
Annex I

Implementing the DTC
Implement and Evaluate the Agreed-upon Intervention

- Type of intervention(s) will depend on the type of medicine use problem and the underlying reasons for it that have been identified.
- Treatment guidelines, EML, educational strategies, regulatory interventions.
- Implement and evaluate interventions with the full cooperation and involvement of stakeholders and senior prescribers.
- If possible, measure the cost of the intervention and any savings in terms of less drug used or different drugs used.

Implementing the DTC - Factors Critical to Success

- Establish clear goals and purpose.
- Obtain wide representation on the committee - physicians, nurses, pharmacists, and administration; obtain motivated participants and dynamic chairperson.
- Permit no relation between committee and pharmaceutical manufacturers or suppliers.
- Communicate all DTC information, policies, procedures, recommendations, and actions to staff.
- Obtain official status from the administration (HIV/AIDS hospital director or regional health board) with strong management support.
- Develop medical and pharmacy departments and local professional schools.
- Ensure contextual incentives.

Summary

- DTC are critical to managing and improving the ways medicines are used at the health system, health facilities, prescribers and end-users.
- Benefits are numerous including:
  - Ensures use of effective, safe, high quality, cost-effective medicines for the hospital (uses medicines from the approved national EML).
  - Monitoring and identification of medicine use problems.
  - Management and containment of antimicrobial resistance.
  - Management of adverse medical events.
  - Management of pharmaceutical expenditures.

Summary (2)

Getting a DTC started or making it more functional will require a strategy based on:

- Local conditions.
- Local data.
- Starting small and then scaling up.
- Choosing a problem that can easily be addressed.
- Transparent decision making.
- Political and administrative support.